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                               ABSTRACT 
 
 
Recent trends in reperfusion in STEMI (ST elevation myocardial 
infarction) in a South Indian tier-3 city. 
Background:  Coronary artery disease is the leading cause of death in both 
the developing and developed countries. India is going to have a large 
proportion of the total number of such cases in the world in the near future. 
In India, larger proportions of patients with acute coronary syndromes 
(ACS) present with ST-elevation myocardial infarction (STEMI) compared 
to patients in the developed countries. The best treatment for STEMI is 
reperfusion with percutaneous coronary interventions (PCI). Facilities for 
PCI are not available in many tertiary care centres in India. We sought to 
study the recent trends of reperfusion in patients of acute STEMI in Vellore, 
a tier-3 South Indian city. 
 
Methods: 1459 consecutive patients presenting with acute STEMI to our 
centre were enrolled. Their demographic profile, risk factors and mode of 
reperfusion were recorded. The study period from August 2008 to July 2010 
was divided into four half-years and trends of reperfusion were compared 
over this study periods. 
 
Results:  Mean age of study population was 56.3+11.8 years. There were 
1214 (83%) males and 245 (17%) females.  The largest number of patients  
were in the age group of 40-59 years  (313, 50%).  1255 (86%) of patients 
received some form of reperfusion therapy either by thrombolytic agent or 
PCI. Thrombolysis with streptokinase in 1019 (69.8%) patients was the most 
common mode of reperfusion therapy used.  This was followed by primary 
2 
 
PCI which was used in of 137 patients (9.4%) and tenecteplase in 99 (6.7%) 
patients.  204 (13.8%) did not receive any form of reperfusion therapy for 
various reasons, the most common being late presentation in 175 (85.7%). 
Number of patients presenting with STEMI increased from 297 in the first 
half-year to 465 in the last half-year. The PCI numbers also increased from 
19 in the first half year to 45 in the last half year. Use of tenecteplase as a 
thrombolytic agent remained constant inspite of rising STEMI case load. 
The most common territory involved in STEMI was anterior wall 
593(58.2%). 
 
Conclusion: Patients presenting with STEMI in this study were on an 
average a decade younger than western population. There was about 20% 
increase in STEMI every year in the present study. Younger patients are 
least likely to receive primary PCI or tenecteplase as reperfusion therapy. 
86% of patients received some form of reperfusion therapy and streptokinase 
was the most common type of reperfusion therapy used. Primary PCI rates 
increased at 20% per year during this study but still <10% of STEMI 
patients receive it. Tenecteplase which is superior to streptokinase as a 
thrombolytic agent was used in less than 10% of patients due to high cost.  1 
in 8 patients of STEMI did not receive any form of reperfusion therapy; the 
most common reason for this was late presentation. 
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           INTRODUCTION   
 
Coronary artery disease (CAD) is the most common cause of death in both 
developing & developed countries 1. By 2020 IHD is expected to increase by more 
than 120% in the developing countries as compared to 30-40% in the developed 
countries 2. 60% of the world’s heart disease is expected to occur in India 3. This 
will place a huge strain on healthcare resources which are already inadequte and 
overstretched. Providing IHD patients optimal care in the Indian setting requires 
specific and relevant data applicable to the general population.  
       The spectrum of IHD in the developed countries appears to be different from 
that in the Indian population. Fewer than 40% of the patients with acute coronary 
syndrome present with ST-segment elevation myocardial infarction (STEMI) in the 
developed countries 4,5  and this is also showing a decreasing trend with time. On 
the other hand 60% of patients with ACS present with ST segment elevation 
myocardial infarction in India. In patients with ST elevation myocardial infarction, 
the main consideration in treatment is reperfusion which is influenced by duration 
from onset of symptoms.  The best treatment for patients presenting with STEMI is 
reperfusion either in the form of primary percutaneous coronary intervention (PCI) 
or by means of thrombolytic agents. Primary PCI re-establishes blood flow in the 
culprit coronary artery by mechanically dislodging the thrombus obstructing the 
vessel, and has been shown consistently in all studies to be superior to 
thrombolysis.  Primary PCI is not available in most tertiary care centres in India. 
So in most centres treatment of STEMI is based on pharmacological thrombolysis 
by using  streptokinase or tenecteplase.  
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       Most data on patients with acute coronary syndromes are derived from several 
large registries 8,9,10,11,12,13,14,15,16 from developed countries. There are a few small 
studies from India restricted to a few hospitals 17,18,19. We present data from a  
registry of more than 1450 patients with STEMI who presented to CMC Vellore  
looking at the treatment modalities used for reperfusion. 
 5
              AIMS AND OBJECTIVES 
 
 1:-  To evaluate the current trends in revascularization            
            in STEMI in a tertiary care centre in South India.  
 2:-  To assess the number and proportion of patients           
           receiving pharmacological or invasive reperfusion  
           treatment of STEMI. 
 3;-  To assess the number of patients not receiving any 
          form of reperfusion therapy and the reasons for the  
          same.  
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REVIEW OF LITERATURE 
 
EPIDEMIOLOGY 
 
The second half of the 20th century witnessed a global spread of the coronary 
artery disease (CAD) epidemic especially in developing countries, including 
India. The underlying pathology of CAD is atherosclerosis, which develops over 
many years and is usually advanced by the time symptoms occur, generally in 
middle age. Acute coronary and cerebrovascular events frequently occur 
suddenly, and are often fatal before medical care can be given.           
    Of an estimated 58 million deaths globally from all causes in 2005, 
cardiovascular disease accounted for 30%23, 24. This proportion is equal to that due 
to infectious diseases, nutritional deficiencies, and maternal and perinatal 
conditions combined20. It is important to recognize that a substantial proportion of 
these deaths (46%) were in people under 70 years of age, in the more productive 
period of life21.  Globally, CAD was the leading killer in the age group > 60 years, 
and, with 1332000 deaths in adults aged 15-59 years, CAD was ranked behind 
HIV/AIDS only22.  The principal cardiovascular disorder responsible for the 
global rise in mortality is atherosclerotic vascular disease rather than rheumatic 
heart disease. CAD is the leading cause of death in the world, and cerebrovascular 
disease is the second leading cause23,24.  
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CARDIOVASCULAR DISEASE IN INDIA 
 
At the threshold of the new millennium the threat of CAD is looming large as this 
new epidemic afflicts Indians at a relatively younger age with severe and diffuse 
forms of lesions. Recently, the subject of CAD in Indians (referred to as immigrants 
or Asian Indians or South Asians when outside India) has become a challenge for 
many research centres worldwide25,26. The prevalence of CAD has progressively 
increased in India during the latter half of the last century, The prevalence of CAD 
is two times higher (10%) in urban than in rural India 29,30. South Indians have 
higher prevalence, 7% in rural and 14% in urban areas. The vulnerability of urban 
Indians to CAD is possibly related to different nutritional, environmental, and life-
style factors.  Unfortunately, the on-going urbanization of rural India is likely to 
narrow down these differences31. 
India is in the midst of a demographic transition. The average life expectancy at 
birth in India is 63.7 years, being 63.1 for males and 64.4 for female, compared 
with the  national average of 41.2 years in 1951-196122. The demographic transition 
has led to an increase in the number of older people (aged >60 years), from 19.61 
million in 1950 to 75.93 million in 2000. The increase in life expectancy has 
brought a large section of population to an age where cardiovascular disease starts 
manifesting itself. In India CAD rates have increased during last 30 years, whereas 
declining trends have been noticed in developed western countries22.  
Reports on CAD in Indians from different parts of the world have shown that 
Indians are at 3-4 times higher risk of CAD than white Americans, 6 times higher 
than Chinese, and 20 times higher than Japanese25,26,27. The exact prevalence of 
CAD in India is difficult to estimate owing to the lack of large population based 
studies.  Absence of a centralized death registry for CVDs and irregularities in 
completion of death certificates also hamper estimation of the actual burden of 
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CVD. Heart diseases  occur in Indians 5 to 10 years earlier than in other populations 
around the world28. According to the INTERHEART study, the age at first 
presentation of acute MI in the south Asian (Bangladesh, India, Nepal, Pakistan, Sri 
Lanka) population is 53 years, whereas that in western Europe, China, and Hong 
Kong is 63 years, with men more than women affected32. The first myocardial 
infarction (MI) occurs in 4.4% of Asian women and 9.7% of men at age less than 
40 years, which is 2 to 3.5 fold higher than in the west European population and is 
third highest of all the regions studied worldwide32. 
The INTERHEART study32, involving 52 countries, established an association 
between conventional modifiable risk factors for MI in all regions of the world, 
including South Asia, and in both sexes and at all ages. In South Asians, 
apolipoprotein (Apo) B/ApoA1 ratio and smoking were the important risk factors, 
as in the rest of the world. However, hypertension, abdominal obesity, and diabetes 
had more severe effects in South Asians. The study also showed that hypertension 
and diabetes were more important risk factors in younger Indian women than men. 
It was also observed that the risk of CAD increased incrementally with smoking and 
it was a greater risk factor in younger men than in women. 
Several factors appear likely to have contributed to the acceleration of CAD 
epidemic in India in recent times. These are:  
(i) Demographic transition to an older population, as a result of  
increasing life expectancy  
(ii) Confluence of both conventional risk factors and non-
 conventional risk factors in Indians 28. 
Conventional factors like hypertension, diabetes, hyper-cholesterolemia, smoking 
etc. owe their origin to growing urbanization and western 'acculturation' amongst 
Indians.  
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         Non-conventional risk factors like hyper-insulinemia, insulin resistance, 
lipoprotein A etc. are determined by genes or other 'programming' factors and 
their high prevalence amongst Indians probably explain the malignant, precocious 
nature of CAD that typically affects Indians. Recently a relationship between low 
birth-weight, which is widely prevalent amongst Indian newborns, and enhanced 
susceptibility to CAD in adult life ('Barker hypothesis') has been found.  These 
multiplicative effects of conventional and emerging risk factors appear to provide 
a plausible explanation for the excess burden of CAD among Indians, many of 
whom are lean, non-smoking, vegetarian33.  
Cardinal features of coronary artery disease among Indians compared to other 
populations33: 
Higher rates 
• 2 to 4 fold higher prevalence, incidence, hospitalization, mortality 
Greater prematurity 
• 5 to 10 years earlier onset of first Ml 
• 5 to 10 fold higher rate of Ml and death in young <40 years of age) 
Greater severity33 
• three vessel disease common even among young premenopausal women 
• large Ml with greater muscle damage 
Higher prevalence of glucose intolerance 
•  insulin resistance syndrome, diabetes, central obesity 
Lower prevalence of conventional risk factors 
•     hypertension, obesity, cigarette smoking 
•    cholesterol levels: similar to Whites but higher than other     Asians 
Higher prevalence of emerging (thrombogenic) risk factors 
• high levels of lipoprotein A,  homocysteine,  apoprotein B 
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• high levels of triglycerides, fibrinogen 
• low levels of HDL 
• small dense LDL 
Higher rates of clinical events for a given degree of  atherosclerosis 
• double that of whites 
• four fold higher than Chinese 
• higher proportion of unstable or vulnerable plaques 33 
The 4 main risk factors, which showed consistently significant associations across 
all south Asian countries in both sexes were current and  former smoking, high 
ApoB100/Apo-I ratio, history of hypertension and history of diabetes.         
Between 1990 and 2020, CAD is expected to increase by 120% in women and 
137% in men in developing countries, compared to 30-60% in developed countries2.  
In addition, the proportion of patients with STEMI at 60% of the acute coronary 
syndrome patients is much higher than the proportion observed in developed 
countries where fewer than 40% had STEMI5. This suggest that patients with acute 
coronary syndrome in India are likely to have worse prognosis than patients in 
western countries. Also, the average age of acute coronary syndrome patients in 
India at 57 years is also much lower than that in western countries. Patients in India 
also take longer time to reach hospitals, and for initiation of treatment. The majority 
of patients of MI in India receive thrombolytic therapy for reperfusion while only 
8% of STEMI patients are treated with primary PCI.  Correspondingly the 30 days 
mortality rate in Indian patients with MI is higher than in registries in   high income 
countries6. 
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Myocardial Infarction 
 Atherosclerosis is the gradual buildup of cholesterol and fibrous tissue in plaques 
in the wall of arteries (in this case, the coronary arteries), typically over decades35. 
Blood stream column  irregularities visible on angiography reflect artery lumen 
narrowing as a result of decades of advancing atherosclerosis37. Plaques can become 
unstable, rupture, and additionally promote a thrombus that occludes the artery; this 
can occur in minutes. When plaque rupture occurs, it exposes the intimal layer and 
initiates a cascade of platelet activation and thrombosis resulting in occlusion of the 
vessel and infarction of the subjacent myocardium38. Acute myocardial infarction 
refers to two subtypes of acute coronary syndrome:  non-ST-elevation myocardial 
infarction and ST-elevation myocardial infarction, which are most frequently (but 
not always) a manifestation of atherosclerotic coronary artery disease34. Myocardial 
infarctions are usually classified by size: microscopic (focal necrosis), small (<10% 
of the left ventricle myocardium), moderate (10-30% of the left ventricle 
myocardium), and large (>30% of the left ventricle myocardium), and by location38. 
Pathology of myocardial infarction 
Myocardial infarction can be classified pathologically as acute, healing, or healed. 
Acute myocardial infarction is characterized by the presence of polymorphonuclear 
leukocytes. The presence of mononuclear cells and fibroblasts, and the absence of 
polymorphonuclear leukocytes characterize healing  infarction. Healed infarction is 
manifested as scar tissue without cellular infiltration. The entire process leading to a 
healed infarction usually takes at least 5-6 weeks. Reperfusion may alter the 
macroscopic and microscopic appearance of the necrotic zone by producing 
myocytes with contraction bands and large quantities of extravasated erythrocytes.  
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     Myocardial infarction can be classified temporally as evolving (<6 h), acute (6 h-
7 days), healing (7-28 days), and healed (29 days and beyond)32.   
 
Reference 40 
A 2007 consensus document classifies myocardial infarction into five main types 
39 : 
Type 1 - Spontaneous myocardial infarction related to ischaemia due to a primary 
coronary event such as plaque erosion and/or rupture, fissuring, or dissection  
Type 2 - Myocardial infarction secondary to ischemia due to either increased 
oxygen demand or decreased supply, e.g. coronary artery spasm, coronary 
embolism, anemia, arrhythmias, hypertension, or hypotension  
Type 3 - Sudden unexpected cardiac death, including cardiac arrest, often with 
symptoms suggestive of myocardial ischemia, accompanied by presumably new 
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ST elevation, or new left bundle branch, or evidence of fresh thrombus in a 
coronary artery by angiography and/or at autopsy, but death occurring before 
blood samples could be obtained, or at a time before the appearance of cardiac 
biomarkers in the blood. 
Type 4 - Associated with coronary angioplasty or stents:          
Type  4a  -    Myocardial infarction associated with PCI               
 Type 4b - Myocardial infarction associated with stent thrombosis as             
documented by angiography or at autopsy  
Type 5 - Myocardial infarction associated with coronary artery bypass grafting. 
     The ST segment of the cardiac cycle represents the period between 
depolarization and repolarization of the left ventricle. In the normal state, the ST-
segment is isoelectric relative to the PR segment & most  ST-segment elevation is 
a result of non-AMI causes. A study showed that of 123 adult chest pain patients  
with ST-segment elevation ≥ 1mm, 63 patients (51%) did not have myocardial 
infarctions. These non-MI patients had were mainly left bundle branch block 
(LBBB) (21%) and left ventricular hypertrophy (LVH) (33%). 
 
Causes of ST- Segment Elevation41 
 
 Acute Pericarditis 
 Benign Early Repolarization 
 Left bundle branch block with acute MI (Sgarbossa et al’s  criteria) 
 Left ventricular hypertrophy 
 Left ventricular aneurysm 
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 Brugada syndrome 
 Hyperkalemia 
 Hypothermia 
 Central nervous system pathologies 
 Prinzmetal angina 
 Post electrical cardioversion 
 
Acute Myocardial Infarction 
ST- segment elevation is measured: 
 At J point – if relative to PR segment 
 At 0.06 – 0.08s from J point – if relative to TP segment 
Many studies have been put forward with different ST-segment elevation levels 
indicating as significant for diagnosis of ST-segment elevation myocardial  
infarction  
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ST Segment Elevation Criteria 42 
 
Study Minimum 
Consecutive 
Leads 
Minimum ST Elevation 
(mm) Limb leads 
Minimum 
ST 
Elevation 
(mm) 
Precordial 
leads 
AHA/ACC 2 1 1 
GISSI-1 1 1 2 
GISSI-2 1 1 2 
GUSTO 2 1 2 
TIMI 2 1 1 
TAMI 2 1 1 
Minnesota 
Code 
1 1mm:I,II,III,Avl,avf,V5-
6 
 
  2mm:V1-4  
 
 
 
Irrespective of which definition  is used, ST elevation has poor sensitivity for AMI 
where up to 50% of patients exhibit ‘atypical’ changes at presentation including 
isolated ST depression, T inversion or even a normal ECG. 
 
ST- segment elevation MI occurs due to persistent complete occlusion of an artery 
supplying a significant area of myocardium without adequate collateral circulation  
in  comparison to unstable angina (UA)/ non ST- segment elevation myocardial 
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infarction (NSTEMI),  which result from non-occlusive thrombus, small risk area, 
brief occlusion, or an occlusion with adequate collaterals 
 
Morphology of ST-segment elevation 
Convex ST-segment is more suggestive of  myocardial infarction as compared to 
concave ST- segment elevation 
 
Benign Early Repolarization 
Benign early repolarization is seen most commonly in young black population. It 
is often confused with ST elevation myocardial infarction (STEMI). 
 
ECG characteristics of benign early repolarization43 
1: ST- segment elevation <2 mm 
2: Concavity of initial portion of the ST- segment 
3: Notching or slurring of the terminal QRS complex 
4: Symmetrical, concordant T wave of large amplitude 
5; Widespread or diffuse distribution of STE (does not demonstrate 
territorial distribution) 
6: Relative temporal stability 
 
Distribution 
ST- segment elevation due to acute myocardial infarction (MI)  
usually demonstrate regional or territorial pattern 
o Anterior MI – V3-V4 
o Septal MI – V2-V3 
o Anteroseptal MI – V1/2 – V4/5 
o Lateral MI – V5/V6 
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o Inferior MI – II, III, aVF 
Diffuse ST-segment elevation suggestive of non MI causes, e.g. pericarditis43. ST-
elevation myocardial infarction is difficult to diagnose in presence of left bundle 
branch block. Sgarbossa criteria was put forward to diagnose myocardial 
infarction in presence of left bundle branch block (LBBB) 43. 
 
Sgarbossa Criteria42 
 
ST Elevation ≥ 1 mm and 
concordant with QRS complex 
Score 5 points 
Odds Ratio (OR) 25.2 
ST Depression ≥ 1 mm in V1, V2, 
V3 
Score 3 points 
OR 6.0 
ST Elevation ≥ 5 mm and discordant 
with QRS complex 
Score 2 points 
OR 4.3 
 
 
A total score of 3 or more suggests that the patient is likely      experiencing an 
AMI based on the ECG criteria. With a score less than 3, the ECG diagnosis is 
less certain requiring additional evaluation. Subsequent publications have 
suggested that Sgarbossa’s criteria is less useful than reported, with studies 
demonstrating decreased sensitivity and inter-rater reliability 
Reperfusion Strategy in Myocardial Infarction  
Coronary atherosclerosis is a diffuse process with segmental lesions called coronary 
plaques. The plaque ruptures, denuding the endothelial lining, and allows 
prothrombotic enzymes and molecular triggers to mix with the blood. Platelets are 
activated, and the coagulation cascade is amplified resulting in a thrombus that 
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occludes the vessel, preventing the circulation of oxygenated blood. Irreversible 
ischemia-induced myocardial necrosis may occur within 20-60 minutes of 
occlusion. The mainstay of treatment is reperfusion therapy through administration 
of fibrinolytics (pharmacologic reperfusion) or primary percutaneous coronary 
intervention ‘(PCI) (mechanical reperfusion). Evidence exists that expeditious 
restoration of flow in the obstructed infarct artery after the onset of symptoms in 
patients with STEMI is a key determinant of short- and long- term outcomes 
regardless of whether reperfusion is accomplished by fibrinolysis or PCI 42,43,44. A 
critically important goal of reperfusion is to restore flow in the infarct artery as 
quickly and  completely as possible, but the ultimate goal of reperfusion in STEMI 
is to improve myocardial perfusion in the infarct zone. Despite adequate restoration 
of flow in the epicardial infarct artery, perfusion of the infarct zone may still be 
compromised by a combination of microvascular damage and reperfusion injury 
45,46.  
Microvascular damage occurs as a consequence of downstream embolization of 
platelet microemboli and thrombi followed by the release of substances from 
activated platelets that promote occlusion or spasm in the microvasculature. 
Reperfusion injury results in cellular edema, free radical formation, calcium 
overload, and acceleration of the apoptotic process. Cytokine activation in the 
infarct zone leads to neutrophil accumulation and inflammatory mediators that 
contribute to tissue injury. 
Time from onset of symptoms to fibrinolytic therapy is an important predictor of 
MI size and patient outcome 47. The efficacy of fibrinolytic agents in lysing 
thrombus diminishes with the passage of time48. Fibrinolytic therapy administered 
within the first 2 hours (especially the first hour) can occasionally abort MI and 
dramatically reduces mortality48,49. Because the benefit of fibrinolytic therapy is 
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directly related to the time from symptom onset, treatment benefit is maximized by 
the earliest possible application of therapy.  
The present recommendations for fibrinolytic therapy say that: In the absence of 
contraindications, fibrinolytic therapy should be administered to STEMI patients 
with symptom onset within the prior 12 hours and ST elevation greater than 0.1 mV 
in at least 2 contiguous precordial leads or at least 2 adjacent limb leads or patients 
with symptom onset within the prior 12 hours and new or presumably new LBBB. 
In the absence of contraindications, it is reasonable to administer fibrinolytic 
therapy to ST-segment elevation MI (STEMI) patients with symptom onset within 
the prior 12 hours and 12-lead ECG findings consistent with a true posterior MI. It 
is also reasonable to administer fibrinolytic therapy to patients with symptoms of 
STEMI beginning within the prior 12 to 24 hours who have continuing ischemic 
symptoms and ST elevation greater than 0.1 mV in at least 2 contiguous precordial 
leads or at least 2 adjacent limb leads7. 
Contraindications and Cautions For Fibrinolytic Use In ST-Elevation 
Myocardial Infarction7 
Absolute contraindications  
• Any prior intra-cerebral haemorrhage  
• Known structural cerebral vascular lesion (eg, arterio- venous malformation) 
• Known malignant intracranial neoplasm (primary or metastatic) 
• Ischemic stroke within 3 months except acute ischemic stroke within 3 hours 
• Suspected aortic dissection 
• Active bleeding or bleeding diathesis (excluding menses) 
 
 
20
• Significant closed head or facial trauma within 3 months 
Relative Contraindications 
• History of chronic severe, poorly controlled hypertension 
• Severe uncontrolled hypertension on presentation (systolic    blood pressure 
greater than 180 mm Hg or diastolic blood pressure greater than 110mm Hg) 
• History of prior ischemic stroke greater than 3 months,  dementia, or  known 
intracranial pathology not covered in  contraindications 
• Traumatic or prolonged (greater than 10 minutes) cardiopulmonary 
resuscitation or major  surgery (less than 3 weeks) 
• Recent (within 2 to 4 weeks ) internal bleeding 
• Non-compressible vascular punctures 
• For streptokinase/anistreplase : prior exposure (more than 5  days ago) or 
prior allergic reaction to these agents 
• Pregnancy 
• Active peptic ulcer 
• Current use of anticoagulants : the higher the INR, the higher  the risk of 
bleeding 
 
Efficacy of Intravenous Fibrinolytic Therapy In STEMI 
It has been well established that fibrinolytic therapy provides a survival benefit for 
patients with STEMI, based on large, well-controlled clinical trials 47,48,49.  The 
mechanism of benefit, which may have different time dependencies, include 
salvage of myocardium with reduced infarct size, favourable effect on infarct 
healing and myocardial remodeling, and reduced electrical heterogeneity and 
potential for life-threatening ventricular arrythmia50. 
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An overview of the results of 9 trials by the ‘Fibrinolytic Therapy Trialists’ 
Collaborative Group comparing the outcome of patients undergoing fibrinolytic 
therapy and those of controls demonstrated a highly significant 18% relative 
reduction in 35 days mortality (9.6% fibrinolysis versus 11.5% control), which 
corresponds to absolute reductions in 35-day mortality rates of approximately 30 
per 1000 for patients who arrived at the hospital within 6 hours of the onset of 
symptoms and of approximately 20 per 1000 for patients who arrived 7-12 hours 
after the onset of symptoms8.This survival benefit is maintained over the long 
term (up to 10 years).  
 
THROMBOLYTIC AGENTS 
 
The fibrinolytic agents currently approved for treating patients with STEMI 
include streptokinase, alteplase, reteplase, and tenecteplase. Thrombolytic agents 
available today are serine proteases that work by converting plasminogen to the 
natural fibrinolytic agent plasmin. Plasmin lyses clot by breaking down the 
fibrinogen and fibrin contained in a clot. 
 
Streptokinase 
The history of thrombolytic therapy began in 1933 when Tillet and Carner 
discovered that filtrates of broth cultures of certain strains of Streptococcus 
bacteria (beta-hemolytic streptococci) could dissolve a fibrin clot51. Streptokinase 
found its initial clinical application in combating fibrinous pleural exudates, 
hemothorax, and tuberculous meningitis52. In 1958, streptokinase was first used in 
patients with acute myocardial infarction, and this changed the focus of treatment. 
At first, streptokinase infusion produced conflicting results until the Gruppo 
Italiano per la Sperimentazione della Streptochinasi nell'Infarto Miocardico 
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(GISSI) trial in 1986, which validated streptokinase as an effective therapy and 
established a fixed protocol for its use in acute myocardial infarction52.  STK has 
no proteolytic activity of its own and thus activates PG to PN indirectly by first 
forming a high affinity equimolar complex with PG (STK-PG activator complex) 
51. It forms a 1:1 complex with plasminogen causing conversion to plasmin. It is 
non specific, activating circulating as well as clot-bound plasminogen, and causes 
extensive fibrinogen depletion. 
       Streptokinase is antigenic. Neutralizing antibodies are significant following 
use, and repeat administration should be avoided. Allergic reaction (rash, chills, 
urticaria) occurs in around 4% of patients and anaphylactic shock occurs in 0.5% 
of patients 53.  Hypotension can be significant (average decrease ~ 35 mm systolic 
blood pressure (SBP) 54   and may be worsened by rapid administration, which 
excludes bolus use and necessitates constant IV infusion. It is commonly given as 
1.5 million units over 60 min. 
 
Alteplase 
Tissue type plasminogen activator (t-PA) is a naturally occuring serine protease, 
which is produced by healthy endothelium. Its levels are increased with exercise 
and inhibited by plasminogen activator inhibitor (PAI-1). Alteplase is a 
commercially available, genetically engineered, bacterially produced version of 
human t-PA. it exhibits marked specificity for the plasminogen-fibrin complex, 
although at the doses necessary to achieve rapid lysis, there is ~ 50% depletion of 
circulating fibrinogen. t-PA is associated with a higher early recanalization rate 
relative to streptokinase55, but may be accompanied by an increase rate of 
reocclusion56. The half-life is approximately 5 min; thus, t-PA must be 
administered via continuous IV infusion over 90 min. 
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The accelerated dosing regimen has been proven to be the most effective54 : 15 mg 
bolus over 1-2 min followed by 0.75mg/kg IV (< 35 mg) over 60 min. Weight 
adjustment is recommended because of excessive bleeding in lighter weight (<60 
kg) patients and a trend toward decreased lysis in heavy weight (>90 kg) 
individuals55 . Higher dose and double-bolus regimens have been associated with 
unacceptable bleeding rates56,57 . The accelerated or front-loaded dosing regimen 
has been shown to have higher early patency rates, similar safety profile54, and 
lower incidences of reocclusion as compared with the standard dosing regimen 60. 
The TIMI (Thrombolysis in myocardial infarction), phase 1 trial randomly 
assigned 290 patients with evolving acute MI to altepase or to streptokinase. 
Alteplase was far superior in achieving coronary reperfusion; twice as many 
occluded infarct-related arteries opened after 90 minutes with alteplase than with 
streptokinase 61. 
The GUSTO 1 study (41,021 patients) tested the accelerated dose regimen 
combined with intravenous heparin. Despite an increase in intracerebral bleeding 
with t-PA, overall benefit as assessed from the combined endpoint of total 
mortality and disabling stroke was significantly better with t-PA as compared with 
streptokinase (6.3% vs. &.3%)61. This translates into 15% mortality reduction or 
about 10 lives saved per 1,000 patients treated. 
Reteplase 
Reteplase is a deletion mutant of t-PA that exhibits preferential activation of 
fibrin-bound plasmin and a two to threefold increase half-life (15 min), 
permitting bolus administration. It has a lower affinity to fibrin (theoretically 
improving clot penetration), though similar fibrin specificity compared with 
alteplase. While initial studies showed superior infarct artery patency when 
compared with conventional dose t-PA in the RAPID 1 trial62, and accelerated 
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dose t-PA in the RAPID-2 trial 63, the GUSTO III study (15,059 patients) 
showed equivalent 30-day mortality rates with reteplase (7.5%) versus 
accelerated-dose alteplase (7.2%). The rates of the combined endpoint, death, or 
nonfatal MI- disabling stroke were similar: 7.98% and 7.91%, respectively64. 
Reteplase offers the advantage of double-bolus administration: 10 units IV 
followed by another 10 units 30 min later. Additionally, no weight adjustment is 
required. 
 
Tenecteplase 
Tenecteplase was approved by the FDA as a fibrinolytic agent in 2000. This drug 
has a similar mechanism of action as alteplase (tPA). It is the latest thrombolytic 
agent approved for use in clinical practice produced by recombinant DNA 
technology. This drug is a 527 amino acid glycoprotein, which sustained several 
modifications in amino acids molecules. These modifications consist of a 
substitution of threonine 103 with asparagine, asparagine 117 with glutamine, and a 
tetra-alanine substitution at amino acids 296-299 in the protease domain. This 
change permits Tenecteplase to have a longer plasma half-life and more fibrin 
specificity. Tenecteplase has a half-life ranging initially from 20-24 minutes up to 
130 minutes final clearance, most of it by liver metabolism.66  
Because of the amino acid modifications, Tenecteplase has the advantage of a 
single bolus administration and decreased bleeding side effects due to high fibrin 
specificity. The ASSENT-2 trial evaluated the efficacy and safety of tenecteplase 
compared with alteplase in patients with AMI. Tenecteplase was found non-inferior 
to alteplase in terms of 30-day mortality. Tenecteplase was associated with fewer 
bleeding complications, major bleeding events (4.66% vs 5.94%), and lower need 
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for blood transfusion (4.25% vs 5.49%; p=.0002). Rates for intracranial hemorrhage 
were similar (tenecteplase 0.93%, alteplase 0.94%)67. Follow-up study showed that 
mortality rates between the two active therapy groups remained similar after one 
year68.  Its prolonged half-life(~20 min) permits it to be dosed as a weight-adjusted 
30-50 mg single bolus given over 2-5 sec. The recommended dose is 30 mg for 
persons less than 60 kg, 35 mg for 60-70 kg, 40 mg for70-80 kg, 45mg for 80-90 
kg, and 50mg for > 90 kg. As a single-bolus agent, tenecteplase has become the 
most widely used fibrin-specific agent. 
Evidence exists that expeditious restoration of flow in the obstructed infarct artery 
after the onset of symptoms in STEMI patients is a key determinant of short-and 
long-term outcomes regardless of whether reperfusion is accomplished by 
fibrinolysis or PCI37-39. 
Efforts should be made to shorten the time for rapid recognition and treatment of 
patients with STEMI such that door-to needle (or medical contact to needle) time 
for initiation of fibrinolytic therapy can be achieved within 30 min or that door to 
balloon ( or medical contact to balloon) time for PCI can be kept under 90 
minutes. 
 
SELECTION FOR REPERFUSION STRATEGY 
 
Several issues should be considered in selecting the type of reperfusion therapy: 
time from onset of symptoms: time from onset of symptoms to fibrinolytic therapy 
is an important predictor of MI size and patient outcome 66. The efficacy of 
fibrinolytic agents in lysing thrombus diminishes with the passage of time 69. 
Fibrinolytic therapy administered within the first 2 hours (especially the first hour) 
can occasionally abort MI and dramatically reduce mortality 70,71 .  
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Choice of reperfusion therapy is also affected by the patient’s risk of bleeding. 
When both types of reperfusion are available, the higher the patient’s risk of 
bleeding with fibrinolytic therapy, the more strongly the decision favours PCI. If 
PCI is unavailable, then the benefit of pharmacological reperfusion therapy is 
balanced against the risk. STEMI patients presenting to a facility without the 
capability for expert, prompt intervention with primary PCI within 90 minutes of 
first medical contact undergo fibrinolysis unless contraindicated. 
 
Primary percutaneous coronary intervention (PCI) 
 
Primary PCI is defined as percutaneous intervention in the setting of STEMI 
without previous or concomitant fibrinolytic treatment. RCTs and meta-analyses 
comparing primary PCI with in-hospital fibrinolytic therapy in patients within 6–
12 h after symptom onset treated in high-volume, experienced centres have shown 
more effective restoration of vessel patency, less re-occlusion, improved residual 
LV function, and better clinical outcome with primary PCI 72 Cities and countries 
switching from fibrinolysis to primary PCI have observed a sharp decrease in 
mortality after STEMI 73,74. 
American College of Cardiology/American Heart Association (ACC/AHA) 
guidelines specify that primary PCI should be performed by operators who perform 
75  elective procedures per year and at least 11 procedures for STEMI in institutions 
with an annual volume of >400 elective and >36 primary PCI procedures76. Such a 
policy decision is justified by the strong inverse volume-outcome relationship 
observed in high-risk and emergency PCI. Therefore, tolerance of low-volume 
thresholds for PCI centres for the purpose of providing primary PCI is not 
recommended. It is essential to make every effort to minimize all time delays, 
especially within the first 2 h after onset of symptoms, by the implementation of a 
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system of care network. As illustrated in Figure below, the preferred pathway is 
immediate transportation of STEMI patients to a PCI-capable centre offering an 
uninterrupted primary PCI service by a team of high-volume operators. Patients 
admitted to hospitals without PCI facilities should be transferred to a PCI-capable 
centre and no fibrinolytics should be administered if the expected time delay 
between first medical contact (FMC) and balloon inflation is <2 h. If the expected 
delay is >2 h (or >90 min in patients <75 years old with large anterior STEMI and 
recent onset of symptoms), patients admitted to a non-PCI centre should 
immediately receive fibrinolysis and then be transferred to a PCI-capable centre 
where angiography and PCI should be performed in a time window of 3–24 h.77-80 
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Ref 81 
Organization of ST-segment elevation myocardial infarction patient pathway 
describing pre- and in-hospital management and reperfusion strategies within 12 h 
of first medical contact. 
 
SPECIFIC CONSIDERATION 
 
A   Primary PCI should be performed as quickly as possible, with a   goal Of 
medical contact-to-balloon or door-to-balloon time of  with in 90 minutes. 
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B  If the symptom duration is within three hours and the expected door-balloon 
time minus the expected door-to-needle time is: 
i) With in 1 hour, primary PCI is generally preferred. 
ii) greater than 1 hour, fibrinolytic therapy (fibrin-specific agents) is 
generally preferred. 
C  If symptom duration is greater than 3 hours, primary PCI is  generally preferred 
and should be performed with a medical contact-to-balloon or door-to-balloon time 
as brief as possible, with a goal of within 90 minutes. 
D   Primary PCI should be performed for patients younger than 75 years old with 
ST elevation or LBBB who develop shock within 36  hours of  MI and are suitable 
for revascularization that can be performed within 18 hours of shock, unless further 
support is futile because of the patient’s wishes or contraindications/unsuitability 
for further invasive care. 
E  Primary PCI should be performed in patients with severe congestive heart 
failure (CHF) and/or pulmonary edema (killip class 3) and onset of symptoms 
within 12 hours. 
F The medical contact-to-balloon or door-to-balloon time   should be as short as 
possible (i.e., goal within 90 min). Primary PCI is reasonable for selected patients 
75 years or older with ST elevation or LBBB or who develop shock within 36 
hours of MI and are suitable for revascularization that can be performed within 18 
hours of shock.  Patients with good prior functional status who are suitable for 
revascularization and agree to invasive care may be selected for such an invasive 
strategy. 
It is reasonable to perform primary PCI for patients with onset of symptoms within 
the prior 12-24 hours and 1 or more of the following: 
a. severe  CHF 
b. Hemodynamic or electrical instability 
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c. Persistent ischemic symptoms  
 
Pharmaco-invasive therapy  
 
The logistic difficulties of implementing primary PCI in routine practice coupled 
with evidence of benefit of prehospital fibrinolysis (especially if administered early 
after the onset of symptoms) and the overarching importance of time to reperfusion 
regardless of strategy used serve as the foundation for developing a unified 
approach to management of patients with STEMI in the future88-90 . More than one 
decade ago, clinicians were discouraged from proceeding to PCI early after 
fibrinolysis because of lack of benefit of such a strategy and a trend toward worse 
outcomes in several trials 91-93.  Given the advances in PCI described above and 
clinical experience in contemporary practice, early referral for PCI is not only less 
concerning today but is scientifically appealing. The benefits of the synergy of a 
pharmacological approach followed by PCI have been described by Dauerman and 
Sobel94. Shortening the time to reperfusion of the infarct artery by prompt initiation 
of pharmacological reperfusion (either before hospitalization or in the emergency 
department of any hospital) followed by early PCI to consolidate the initial 
reperfusion process and prevent reocclusion of the infarct artery may be the optimal 
reperfusion strategy for patients with STEMI. Two new trials support the use of 
pharmaco-invasive therapy are: the CARESS-in-AMI trial 75and the TRANSFER-
AMI trial76. 
 
Cardiac Enzyme Release 
 
Measurement of cardiac enzyme release had become an integral part of the 
retrospective diagnosis of myocardial infarction, and the peak concentrations are 
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useful in the process of risk stratification. In general, though, they have not proved 
very useful for immediate decision making in the management of acute 
myocardial infarction. A single measurement is not useful and even sequential 
measurements are difficult to interpret as the shape of the release curve relates to 
the time from onset of infarction (which is very variable) and to the thrombolytic 
agent used. There was considerable interest in biochemical tests for diagnosing 
failed thrombolysis. These included creatine kinase isoenzyme 82-84, troponin T83 
or l84, fatty acid binding proteins and myoglobin82-84. Despite the high sensitivities 
and specificities described, none of these tests found favour in routine practice or 
were subjected to a prospective analysis in which the results influenced clinical 
decisions. Frequent blood sampling is often required and the determination of 
reperfusion sometimes depends on complex mathematical models.  
 Reperfusion treatment in acute myocardial infarction aims at early and sustained 
reperfusion of the myocardium at risk. PCI is associated with better outcomes than 
thrombolytics in the form of lower mortality, lower rate of nonfatal reinfarction 
and almost no risk of hemorrhagic stroke. The benefit is in all age groups and the 
elderly benefit more so than the younger groups. The time from symptom onset (to 
hospital presentation) to PCI is important with greatest benefit if occurring within 
90 minutes. It is a treatment that is available to most patients including those in 
cardiogenic shock and high bleeding risk. PCI has the added benefit of identifying 
patients with coronary disease that would be conducive to coronary artery bypass 
grafting. The long and short answer now is that if PCI is available, multiple studies 
have shown enhanced survival compared to thrombolysis with a lower rate of 
intracranial hemorrhage and recurrent MI. Therefore, patients that present with 
STEMI or MI with new onset LBBB consistent within 12 hours of symptom onset 
should move to PCI. Despite this strong evidence, patients with STEMI and no 
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contraindications, reperfusion therapy is underutilized and often not administered 
in a time dependent manner.85 
    Data regarding revascularization in STEMI from India came from study by Jose 
et al 86 and CREATE study 87. The study by Jose et al was a single centre study 
done in CMC Vellore. It enrolled 1320 patients with STEMI with mean age of 
56+13. Males comprised of 83.6% of patients and 82.8% of patients underwent 
reperfusion only by means of thrombolysis.  CREATE registry which was a 
prospective registry done in 89 centres from 10 regions and 50 cities in India. It 
enrolled 20937 patients out of which 12405 (60·6%) had STEMI. The mean age of 
these patients was 57·5 (SD 12·1) years. Most patients were from lower middle 
10,737 (52·5%) and poor 3999 (19·6%) social classes. The median time from 
symptoms to hospital was 360 (inter-quartile range 123–1317) min, with 50 (25–
68) min from hospital to thrombolysis. 6226 (30·4%) patients had diabetes; 7720 
(37·7%) had hypertension; and 8242 (40·2%) were smokers. Percutaneous 
coronary interventions was used in 8·0% in STEMI. Thrombolytics (96·3% 
streptokinase) were used for 58·5% of patients with STEMI. 
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       MATERIAL AND METHODS 
 
Setting: The study was done in Vellore, which is a tier 3 South Indian 
city. This is a single centre study done in the Cardiology department of 
Christian Medical College, a tertiary care centre. The Department of 
Cardiology is equipped with all the required facilities for tackling cardiac 
emergencies and primary PCI. The cardiac catheterization laboratory was 
established almost 45 years back. The cardiac catheterization laboratory 
and interventional cardiologists are available round the clock. The 
department caters around 700-800 patients of acute ST elevation 
myocardial infarction per year. 
  
Participants: All patients of any age who were presented with acute 
STEMI were included in the study. Patients coming with STEMI are 
usually local with poor socioeconomic status.  Affordability of 
interventional procedures is always a problem. As Vellore district covers 
a large rural population, awareness among people about coronary artery 
disease and the recent advances in treatment is deficient.  
 
Variables:  The number of patients thrombolysed with streptokinase, 
tenecteplase or undergoing primary PCI was determined. Their 
percentages, mean and standard deviations were calculated.  The data 
was scrutinized for the trends in revascularization. Please see the data 
collection  sheet enclosed. 
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Data Sources/measurement: Data were collected from the patient 
inpatient and outpatients records as well as the records in the coronary 
care unit (CCU)/chest pain unit (CPU). Patients were divided into  age 
groups of 20- 39, 40-59, 60-79 & >80 years. Other variables that  were 
taken into accounts includes age, gender and risk  factors for coronary 
artery disease.  The number of patients not revascularised and the reasons 
for the same were also studied. 
     Bias- It is a retrospective study 
Sample size: Sample size was calculated using the formula 4PQ/D2, used         
in the CREATE study. P is percentage of patient revascularised in the 
previous study.  Q is 100-P. D is taken as error. 
     Sample size was determined to be 388 in this study 
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       OBSERVATIONS AND RESULTS 
 
 
Between 1st August 2008 and 31st July 2010 a total of 1459 patients with  
ST- segment elevation myocardial infarction (STEMI) were enrolled into 
this study. The demographic characterstics of the patients is presented in 
table 1. The largest number of patients were in the age group of 40-59 years 
(313, 50%). Younger age group included 45 (7.2%) patients. 17 (2.7%) 
patients were >80years.  1255 (86%) of patients received some form of 
reperfusion therapy either by thrombolytic agent or PCI. Thrombolysis with 
streptokinase was the most common mode of reperfusion. 1019 (69.8%) of 
the total STEMI patients were reperfused with it. It was also the most 
common mode of reperfusion all age group categories.  
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 Fig: 1        
 
Management Strategy in STEMI
1019
99
137
204
STK TNK PCI Nil
 
 
 
   This was followed by primary PCI which was used in total of 137 patients 
(9.4%).  The age group in which this modality was most utilized was 40-59 
years (75, 54.7%).  Patients with age >80years were least benefited by PCI 
(3.6%) followed by age group 20-39 years (6.56%).Tenecteplase was used in 
99 (6.7%) patients.  204 (13.8%) did not receive any form of reperfusion for 
various reasons. The most common reason for not receiving reperfusion 
therapy was late presentation in 175 (85.7%) patients followed by 
cardiogenic shock or death in 25 (12.2%). There were 4 patients who were  
denied thrombolytic agents because of contraindications for thrombolysis. 3 
patients had either  recent or associated cerebrovascular  accident and 1 
patient had an associated pericardial effusion. 
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Table 2: Reasons for not utilizing reperfusion therapy 
 
Reasons  Number (n=204) 
Late presentation 175(85.7%) 
Cardiogenic shock and death  prior 
to instituting reperfusion 
25 (12.2%) 
Pericardial effusion 1   (.5%) 
Cerebrovascular accidents 3  (2.2%) 
 
 
Fig: 2 
 
Reasons for not utilizing reperfusion therapy
Late presentation
Cardiogenic shock & death prior to instituting reperfusion therapy
Pericardial effusion
CVA
 
 
 
Table 3: Age Distribution of patients receiving different reperfusion 
strategies 
 
Age groups STK TNK PCI Nil 
20-39 99 2 9 10 
40-59 520 39 75 91 
60-79 382 56 48 89 
>80 18 2 5 14 
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Fig 3: 
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Mean age of patients in the whole study population was 56.3+ 11.8 years.  
Maximum patients were in the  age groups of 40-59 years with least in >80 
years.  
 
Table 4:  Trends of revascularization in STEMI 
 
MONTHS 
* 
Nil (%) STK (%) TNK (%) PCI  (%) Total 
1-6  35 (11.8) 216  (72.7) 27  (9.0) 19 (6.4) 297 
7-12  55  (16.1) 219  (64.2) 25  (7.3) 42 (12.3) 341 
13-18  55  (15.4) 253  (71.1) 21  (5.9) 27 (7.5) 356 
19-24  59  (12.7) 331  (71.1) 26  (5.6) 49 (10.5) 465 
Pvalue 0.075 0.000 0.840 0.001 0..000 
 
* Numbers represent months in serial order from July' 08 to June' 10 
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Patients with STEMI increased progressively in every 6 months assessment. 
It was 297 patients to start with in 1st half-year which became 465 in the last  
half-year. 
 
Fig : 5 
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STK use as thrombolytic agent also followed the total STEMI trends. It was 
216 in the first half-year and became 331 in the last half-year. (Table 5, Fig 
5). The percentage of STEMI patients utilizing streptokinase as a 
thrombolytic agent remained constant throughout the study period and 
corresponded to the rise in patients of STEMI. Patient who did not receive 
any form of revascularization too increased from 32 in the first half-year to 
59 in the last half-year. The use of tenecteplase remained almost the same 
throughout the four half-years. It was 27 in the 1st half-year and 26 in the last 
half-year. 
 
Table 5: Gender Pattern in STEMI 
 
Sex Number Of Patients (%) 
Male 1214    (83) 
Female 245      (17) 
 
 
 
Fig 6: 
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Males (1214, 83%) were involved more commonly than females (245, 17%). 
 
 
Table 6: Gender Percentage for reperfusion strategy 
 
Sex STK (%) TNK (%) PCI (%) Nil (%) 
Male 852  (83.6) 86  (86.8) 122 (89) 50  (24.5) 
Female 167  (16.3) 13  (13.2) 15   (11) 155 (75.5) 
 
 
 
 
Fig : 7 
 
852
167
86
13
122
15
50
155
0%
20%
40%
60%
80%
100%
% of 
patients
STK TNK PCI Nil
Reperfusion methods
Gender percentage for reperfusion 
strategy
Female
Male
 
 
 
In all treatment groups the proportion of males was more than females. In 
the group of patients not reperfused, females were 50 (24.5%), for 
tenecteplase (13, 13%), PCI (15, 11%) and streptokinase 167 (16%). 
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Table 7: Distribution of STEMI 
 
Type of STEMI Number of Patients (%) 
AWMI 893 (61.2) 
IWMI 544  (37.3) 
Others 22    (1.5%) 
 
 
 
 
 
Fig: 8 
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Most common territory involved was anterior wall which  constituted 893 
(61%) patients. Inferior wall STEMI in various  combination was 544 (37%. 
Other territories included  high lateral, isolated posterior wall etc were 22 
(1.5%).49.7% of the patients has type 2 diabetes mellitus.  73% of patients 
had some form of lipid abnormalities. 34% of the patients had hypertension.  
31% of the patients were either current or ex-smoker. 60% of the patients 
have atleast > 2 risk factors. 
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Table 8: Comparison of baseline characterstics and management 
strategy outcomes of patients enrolled in earlier study* from the same 
centre vs present study 
 
Characterstics Earlier study 
N=1320 (%) 
Present study 
N= 1459 (%) 
Age     56+ 13    56.3+11.8 
Males 
 
Females 
    1106 (83.8) 
 
     214 (16.2) 
   1214 (83%) 
 
   245   (17) 
Smoking     569  (43.1)    452   (31) 
Diabetes Mellitus     531 (40.2)    725   (49.7) 
Hypertension     504 (38.2)    500   (34 
Location of MI 
      Anterior wall MI      
         
      Inferior wall MI 
 
    752 (57) 
 
     517 (39) 
 
893 (61.2) 
 
   544  (37.2) 
Reperfusion therapy         
    Thrombolytics 
             STK 
              
             TNK 
 
     PCI                    
     
 
     1093 (82.8) 
 
       Nil   (0) 
 
       Nil   (0)                     
 
 
   1019 (69.8) 
 
99 (6.7) 
 
137  (9.4) 
 
Data are numbers (%) or mean + SD 
• Jose et al 86 
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` 
DISCUSSION 
 
Mean age of presentation of STEMI in present study was 56.3+11.8 years with 
majority of them being males (83%). In the study done by Jose et al, which 
included patients from 1999-2003 in the same centre and the CREATE  registry 
which enrolled patients from 2001-2005, the mean age been 56+13 years and  
57.5+12 years. This is suggesting that mean age of patients has not change over a 
decade even when comparing data from the same centre. Patients enrolled in this 
study presented a decade earlier in comparison to the western data where the mean 
age of presentation has increased from 64.1 years to 66.4 years. Early age of 
STEMI could lead to tremendous loss of productive years and can have a adverse 
outcome on the economy a well as national health.   
  It is noteworthy that only a small percentage of patients in younger age group of 
20-39 years received PCI (6.5%) and tenecteplase (2%) as compared to the 40-59 
years age group (PCI 54.7%, tenecteplase 39.4%) age group. This relates to the 
social status and financial means of  the patients enrolled in the study. Younger 
patients who would be benefited the most in terms of productive life-years saved 
remain the least benefited by recent advances in reperfusion therapy. 
In the present study, women comprised 17% of all patients, which was comparable 
to the proportion of women patients in the CREATE study (18%) and the study by 
Jose et al (16.2%). The data also highlighted the inferior treatment received by 
women in comparison to men, as of the patients who received PCI only 11% were 
women.  Similarly, women comprised 13% of all STEMI patients who received 
tenecteplase as a thrombolytic agent.   
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Trends in STEMI :  
 
There was steady increase in admissions of patients with STEMI over a period of 2 
years which was divided into four half-years for analysis. There was almost 20% 
increase in the number of STEMI, if we compare the first two half-years with the 
last two. This increment raises serious concern that the incidence of STEMI is 
likely to be doubled in less than four years in the local population. There was 
increase of 34 % of STEMI patients from the first half-year to the last. There was 
also parallel increase in the number of patients thrombolysed with streptokinase.  
In the first half-year, streptokinase was used in 72% of patients of all STEMI. This 
percentage remained almost the same (71%) till the last half-year. So even though 
the numbers of patients of STEMI have increased, the role of streptokinase as the 
main thrombolytic agent has remained the same over the 2 years period of study. 
Streptokinase constituted 91% of all thrombolysed cases. This is in comparison to 
data from CREATE study in which thrombolytics (96 % streptokinase) were used 
for 58·5% of patients with STEMI and study of Jose et al in which 82.8% of 
patients received thrombolysis (all with streptokinase). 
           A very important result of this study was the analysis of patients who did 
not receive any reperfusion therapy because of various reasons. 14% patients of 
STEMI did not receive reperfusion therapy over the period of 2 years; there was 
41% increase in the number of such patients between the 1st and the last half-years, 
which is very alarming considering that this number should ideally be expected to 
fall. In comparison, in the study by Jose et al 17.2% patient did not receive 
reperfusion therapy.  So even a decade after the study by Jose et al, the reperfusion 
therapy usage in STEMI has only marginally increased. The most important 
reasons for no reperfusion therapy usage was late presentation (85.7%) (Table 2, 
fig 2). There were many reasons for this, such as late diagnosis and referral, poor 
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transport facilities and lack of awareness in the general population.  Even though, 
females formed only 17% of all STEMI patients, they constituted 25 % of patients 
not receiving reperfusion therapy. So reperfusion therapy usage rates were lower in 
female patients as compared to males.        
  Cardiogenic shock and death prior to instituting reperfusion therapy (12.2%) was 
the second most common cause for not receiving reperfusion therapy. These 
patients could have been treated with primary PCI, if they could have afforded it. 
High cost of PCI procedures and its non-availability even in some tertiary care 
centres remains one of the important draw backs in management of STEMI in 
India.         
        There were 3 patients who had an absolute contraindication to thrombolytic 
therapy. Two of them had a recent cerebrovascular accident and one had a 
concurrent large ischemic stroke. One patient was not offered thrombolysis in view 
of large associated pericardial effusion. PCI would have been the best option in 
these of patients, if they could afford it.  Tenecteplase was used in 6.7% of 
patients, where as in the study by Jose et al study the only thrombolytic used was 
streptokinase. The number of patients who were thrombolysed with tenecteplase 
remained almost same in the four half-years studied (Table 4, Fig 4).   
Tenecteplase was used in 9% of all STEMI patients in the first half-year compared 
to only 5.6% in the last (Table 4). The cost of tenecteplase was the reason for 
fewer patients being thrombolysed with it. The cost of tenecteplase in our centre is 
7-8 times that of streptokinase. Interestingly, it was found that most of the patients 
who could afford tenecteplase, could afford PCI as well and so opted for the latter. 
So if tenecteplase is to replace streptokinase as a thrombolytic agent in India, its 
price has to come down significantly.        
          Primary PCI was used in 9.4% of patients as a reperfusion modality. There 
was 20% increase in primary PCI between first and 2nd year of study.  In the 1st 
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half-year PCI was used only in 6.3% of all STEMI patients and this percentage 
increased to 10.5% in the last half-year. So even though the percentage of primary 
PCI between 1st and the last half-year has almost doubled, this may not be adequate 
considering 34% increase in the rates of STEMI hospitalizations during this period.   
          This study also analyzed the main risk factors for CAD prevalent in the 
Indian population. Diabetes mellitus was found in 49.7% of patients; systemic 
hypertension was found in 34%; 31% of patients were either current or ex-smokers 
and 73% of patients had some form of dyslipidemia. This data is different from 
data from CREATE study where 34% patients had diabetes; 37·7% had 
hypertension; and 40·2% were smokers.  Study from Jose et al from the same 
centre as the present study a decade back showed 40.2% prevalence of diabetes in 
STEMI patients. So data the from present study demonstrates an increase in the 
proportion of patients  with diabetes as compared to the past studies and suggest a 
strong correlation of diabetes mellitus with coronary artery disease.       
 There were many differences between the present study and the study by Jose et al 
and the CREATE registry.  The study by Jose et al was done a decade ago in the 
same centre as the present study.  Thrombolysis with streptokinase was the only 
mode of reperfusion in patients of STEMI, where as in the present study STK is 
considered as a last option for reperfusion therapy after PCI and tenecteplase. Data 
on gender and territory of MI has remained almost the same in the two studies. 
Prevalence of diabetes mellitus has increased 10% in STEMI patients over a 
decade which may be the reason for increased number of patients presenting with 
STEMI in the present study. The present study differed from the CREATE registry 
as it is a single-center study as compared to the multi-centre CREATE registry.     
            The present study highlights the current scenario of STEMI and its 
management in a tier 3 South Indian city.  Even with a tertiary care centre with 
cardiac catheterization laboratories and experience cardiologists available 24 hours 
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a day, the rates of primary PCI has been low.  Many reasons are responsible for 
this.  The most important being the financial constraints of the patients; most 
patients in India pay for emergency medical expenses themselves and lack 
insurance cover. 
           Lack of awareness in general population and poor referral and transport has 
an important role to play.  Increasing the numbers of tertiary cardiac centres alone 
is unlikely to be sufficient to improve the management of STEMI; the efforts have 
to be made in all directions. 
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Conclusions 
 
1. : Patients with STEMI in this study are decade younger than western        
population 
2. : 20% increase in STEMI every year in the studied population. 
3. : Younger patients least likely to get primary PCI or tenecteplase as   
reperfusion therapy. 
4. : 86% of patients received some form of reperfusion therapy. 
Streptokinase was the most common type of reperfusion therapy. 
5. : Primary PCI rates increasing at 20% per year but still <10% STEMI 
patients receive it. 
6. : Tenecteplase is a better replacement for streptokinase was used in 
less than 10% due to its high cost. 
7. : 1 in 8 patients of STEMI didn’t receive reperfusion therapy. Most 
common reason for not receiving reperfusion therapy was late 
presentation. 
8. : Almost 50% of STEMI patients had diabetes mellitus. 
9. : 3/5th of STEMI were anterior wall STEMI. 
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                              DATA COLLECTION FORM 
 
 
 
Patient Name- 
Hospital No.- 
Age- 
Weight- 
Sex- 
Date of Admission- 
Date of Discharge-   
Baseline Parameters: 
 
Reperfusion :        Yes/No 
 
PCI :                     Yes/No 
 
Thrombolysis:       STK/TNK 
 
Chest pain to Reperfusion time: 
 
Risk Factors:   DM 
                         HTN 
                         Smoker 
                         Dyslipidemia 
                         Others 
 
Infarct location: AWMI 
                            IWMI 
                            ASMI 
                           LWMI 
                            Others 
 
 
 
 Safety:             Any bleeding 
                          Stroke 
                          Any other ADR  
 
Reasons for no thrombolysis:   Late presentation 
                                                  Cerebrovascular accidents 
                                                  Increase risk of bleeding 
                                                  Pericarditis 
                                                   Others 
 
August 2008                                MASTER CHART 
NAME A/S H.NO MI LYSED AGENT DM HTN DYS SMK 
SADASIVAM 50/M 283485D AWMI YES STK - - - + 
ZOHARA BEE 67/F 172071D AWMI YES STK + + + - 
MANOHARAN 55/M 284103D AWMI YES STK + + - - 
SUBRAMANI 36/M 221421C IW+RV YES STK - + + + 
RATHAKRISHNAN 62/M 287032D AWMI YES STK + + + - 
VIJAYAN  51/M 307080C LWMI NO - - + - - 
KESAVAN 49/M 287067D AWMI YES STK + - - - 
DURAI SWAMY 61/M 287071D AWMI YES STK + + - - 
PALANI 36/M 528348C IWMI YES STK - - + + 
MAYAMMAL 60/F 287091D IWMI YES STK + + - - 
SELVAM 42/M 287205D IW+RV+PW YES TNK + + - + 
RAJU 72/M 287207D ASMI YES STK  - + + 
RATHINAM 90/M 287218D AWMI NO TNK + - + - 
PERSNANDAN 50/M 277052B ASMI YES STK - - - + 
MUNISWAMY 83/M 290003D IW+RV+PW NO TNK - + + - 
VIOLET JAMUNA 45/F 552259C IWMI NO THK + + - - 
RAMAKRISNAN 61/M 127986D AWMI YES STK - - + + 
Md YEHAYA 65/M 287275D AWMI YES STK + + - - 
NALINI 50/F 290203D IW+RV YES STK + + - - 
ARULAPPAN 65/M 290207D IWMI YES STK - - - + 
DHIRENDRA 55/M 286023D AWMI  YES STK - + + + 
CHINNAIAH 47/M 293059D LWMI NO - -  -  
MOHAN RAJ 34/M 286023D IW+RV YES STK + + + + 
MAHADEB 44/M 295337D IWMI YES STK +  + + 
BASKARAN 40/M 294472D AWMI NO - -  - - 
PONNAPAN 58/M 295303D ASMI NO - + + + - 
SHANTHI 45/F 960884C AWMI NO - + - + - 
PURUSOTHMAM 86/M 489091B IWMI NO - + - + - 
PRABHU 40/M 295587D IWMI YES STK - + - - 
KUPPAM 54/M 365778B AWMI YES STK - - + + 
SRINIVASAN 47/M 767313C IW+RV NO - + - - + 
JOTHI 46/F 299038D AWMI YES STK + + - - 
NATARAJAN 58/M 299067D IW+RV+PW YES STK - - + - 
RAJA 52/M 299133D IW+RV+PW YES STK - + - - 
ELUMALAI 33/M 299204D AWMI YES STK - + - + 
YAMUNA BAI  59/M 299278D IW+RV YES STK - + - - 
KANNAN 62/M 303066D ASMI YES STK + - - + 
PITCHAI 51/M 302684D AWMI YES STK - + + - 
PERIYASWAMY 75/M 303735D ASMI YES STK + + - - 
SUBRAMANI 60/M 342740B AWMI YES STK + + - + 
RAGINI 45/F 303268D AWMI YES STK + - - - 
SEPTEMBER 2008          
 
NAME A/S H.NO MI LYSED AGENT DM HTN DYS SMK 
KUPPAMAL 85/F 306024D PW+RV YES STK + + - - 
JAYARAMAN 64/M 700917B AWMI YES STK - + - + 
SALAMMAL 80/F 305561D AWMI NO - - - - - 
ANANDA 52/M 307622D IWMI YES STK + - - - 
JAGADEESAN 42/M 299274D AWMI YES STK - + - + 
SAMASIVAM 60/M 308013D AWMI NO - - + - + 
PANEERSELVAM 48/M 308025D IW+RV YES STK + + - - 
CHARLY VINCENT 34/M 308038D ASMI YES STK + - - - 
CHANDRASEKAR 51/M 308069D AWMI YES STK + - - - 
MANORAMAM 75/F 309489D AWMI YES STK - - + - 
RAJA N. 54/M 310124D AWMI YES STK + - - + 
SAROJA 63/F 649959B AWMI NO - + + + - 
BOOPALAN 50/M 311895D ASMI NO - - - - + 
NATHAN 70/M 311927D AWMI YES STK + - - - 
BEEMA RAJ 70/M 313283D ASMI YES STK + - - + 
ELUMALAI 40/M 311982D IW+RV YES STK - - - + 
KESAVAN 60/M 218195C IW+PW+RV YES STK + + - - 
SUBRAMANI 56/M 314008D IW+RV+PW NO - + + - - 
PARANTHAMAN 69/M 993358C AWMI YES STK + - + - 
SAROJA 56/F 314487D IW+RV NO - - + + - 
MANI 52/M 314025D IW+RV NO - + - + + 
KOKILA 56/F 601505C AWMI YES STK + + - - 
MOHAN 55/M 893280C IW+RV YES STK + + - - 
SURESH 32/M 317001D AWMI YES STK - - - + 
MANI B. M. 50/M 321097D IWMI YES STK - - + + 
PADMAVATHI 55/F 317099D IW+RV+PW YES STK + + - - 
DEVARAJ 70/M 478359A AWMI N0 - - - + - 
KARUNAKARAN 66/M 316355D ASMI YES STK + + - - 
PAPPA 60/F 317836D IW+RV YES STK + + + - 
MANIRATHNAM 54/M 318085D IW+RV+PW YES STK - - - + 
STALIN 51/M 318111D AWMI YES STK + + - - 
KANNIYAPPA 67/M 318126D AWMI YES STK - + - + 
VEDAGIRI 28/M 303998D AWMI NO - + - + - 
MUNISWAMY 38/M 316557D ASMI YES STK - - - + 
VELU 41/M 318181D IWMI YES STK + - + + 
GUNABALAN 54/M 318172D ASMI YES STK - + - - 
MURUGESAN 52/M 318191D AWMI YES STK - + - - 
SUNDARMURTHY 72/M 641017C AWMI NO - - + + - 
VENKATPRASAD 41/M 321019D IW+RV YES STK - - - - 
PANEERSELVAM 34/M 319521D AWMI YES STK + - - + 
MUSFAQ AHMED 58/M 321076D IW+RV+PW NO - + + - + 
CHINNA THAMBI 60/M 320022D ASMI YES STK - + - + 
JAYA PALAN 58/M 321234D AWMI YES STK - - - + 
MURUGESAN 63/M 321280D AWMI YES STK - + + - 
SALAMMAL 80/F 305561D AWMI NO - + - - - 
RAVI 44/M 323502D AWMI YES STK + - - - 
RAMASWAMY 56/M 990112B AWMI YES STK - - - + 
ABDUL KHUDUS 45/M 322006D ASMI YES STK - - - + 
KADHAR 37/M 323720D IW+RV+PW YES STK + + - + 
CHINNADURAI 55/M 323737D IW+RV YES STK + + - - 
SOORAVEL 70/M 323733D ASMI YES STK + + - + 
A JYOTHI 59/M 323796D ASMI YES STK - + - + 
PUSHPA RANI 55/M 326005D AWMI YES STK + + - - 
SETHU BHASHA 40/M 326017D AWMI YES STK - - - + 
OCTOBER 2008          
 
NAME  A/S H.NO MI LYSED AGENT DM HTN DYS SMK 
IBRAHIM 42/M 326208D AWMI NO - + + - + 
ARUNACHALAM 63/M 326222D AWMI YES STK - + - - 
RAMAMOORTHY 52/M 326225D IWMI YES STK - - + - 
ASOKAN 40/M 297755C AWMI YES STK - + - + 
MARGABANDHU 72/M 234331C IWMI YES STK + - - - 
AKBAR BASHA 50/M 326265D AWMI NO - + - + + 
LALITHA 53/F 957193B IWMI NO - - + - - 
MOHAN 49/M 326289D AWMI YES STK - - + + 
SUKUMAR 55/M 326120D AW+IW+PW YES STK - - - + 
JEYAKUMAR 38/M 326122D IWMI YES STK - - - + 
DOWLATHRAM 61/M 263863C ASMI YES STK + + - + 
MAHENDRAN 46/M 326144D IWMI YES STK - - - + 
VASADARAJ 60/M 327139D AWMI YES STK - + - - 
JAYA KUMAR 29/M 329521D AWMI YES STK - + - + 
PADMANABAN 74/M 329629D AWMI YES STK + + - - 
PAPPATHIAMMAL 65/F 329650D AWMI YES STK + + - - 
AMEER BASHA 46/M 709811C IWMI YES STK - - - + 
BASKAR 60/M 330681D ASMI YES STK + + - - 
SAHEB PEER 60/M 329718D ASMI NO - - + - - 
PREMNATH 54/M 329756D AWMI YES STK + + + + 
PARTHIBAN 45/M 106503D IWMI YES STK + + - - 
DEVI 38/F 329808D AWMI YES STK + - - - 
DEVARAJ 57/M 160793D IW+RV+PW YES STK - - + + 
AKBAR ALI 36/M 329829D IWMI NO - + - - + 
SELVAKUMAR 48/M 331633D ASMI NO - + + - + 
MUNISAMY 55/M 332477D AWMI YES STK - - - + 
SRINIVASAN 74/M 266122D AWMI YES URO - + - + 
NACHAMMAL 52/F 332762D IWMI NO - + - - - 
DHANAMMAL 80/F 332283D AWMI NO - - - + - 
AMEERTHAMMAL 60/F 329889D ASMI YES STK + + - - 
DASA RAJ 63/M 333964D AWMI YES STK - + + - 
DEVA RAJ 59/M 160793D AWMI YES URO + + - - 
PALANI 45/M 334424D AWMI YES STK   + + 
DHANALAKSHMI 65/F 336597D AWMI NO - + - + - 
SADHASIVAM 34/M 336680D IW+RV YES STK - + - + 
KUPPUSWAMY 71/M 335613D IWMI YES STK + + - + 
HABIMUNNISA 55/F 335653D AWMI YES STK - + - - 
RANGAN 56/M 335660D AW+IW YES STK + + + - 
VENKAT REDDY 65/M 335657D IWMI NO - - + - - 
MOHAN 56/M 335710D IW+RV YES STK + + - - 
PARASMOL 40/M 335707D IWMI NO - + + + + 
GOVINDASWAMY 49/M 335738D AWMI YES STK + - + - 
KUPPAMAL 70/F 335772D PW+LW YES STK + - - - 
SANKARAN 72/M 339997D IW+LW YES STK + + + + 
MAGESWARI 47/F 340572D AWMI YES STK + + - - 
JOICE STELLA 38/F 340060D ASMI YES STK - - + - 
DAYALAN 57/M 332707C HLMI YES STK - + - + 
KRISHNAMOORTHY 70/M 340094D AWMI YES STK + + - - 
SURESH 29/M 340137D AWMI YES STK - - - - 
RAJU 48/M 340161D ASMI YES STK - + + + 
GULZAR AHMED 42/M 340164D AWMI YES STK + + - + 
MASILAMANI 62/M 343526D AWMI YES STK - - + - 
JAGADESHWARAISH 62/M 342736D AWMI YES STK + - + - 
SAMRAJ 67/M 343552D AWMI YES STK + + - + 
VENKASWAMY 88/M 343556D IWMI NO - - + + - 
RAJESWARI 52/F 343378D IWMI YES STK + - + - 
KARUNANIDHI 38/M 343622D AWMI YES STK - - + + 
RAJENDRAN 34/M 965973C IW+RV YES STK - - - + 
JANARDHANAN 53/M 343719D IW+RV+PW YES STK - + + + 
LOGANATHAN 46/M 343728D AWMI YES STK - - - + 
NOVEMBER 2008          
 
NAME A/S H.NO MI LYSED AGENT DM HTN Dys SMK 
PADMANABHAN 62/M 343782D IW+RV NO - + + - - 
SAROJA 55/F 347181D AWMI YES STK - - - - 
SELVA RAJ 56/M 960383C IW+RV YES STK + + - + 
KOTTILINGAM 62/M 347202D IW+RV YES STK - + - + 
RATHINAMMAL 73/F 347206D IW+RV NO - - + + - 
GUNDAL REDDY 58/M 347207D AWMI NO - + + - - 
SELVAGANESAN 69/M 347216D IWMI NO - + - - + 
ARUMUGAM 61/M 347276D AWMI YES STK + -- - + 
PUSHPAMMAL 55/F 346753D LWMI YES STK - -  - 
VICTOR 59/M 346726D IWMI NO - + + + + 
BOOPALAN 60/M 349792D ASMI YES STK - + - + 
SIVARAJ 35/M 348754D IWMI NO - - - - + 
MARGABANDHU 60/M 025534D AWMI NO - - - - + 
DHANRAJ 54/M 346798D IW+PW YES STK + + - - 
CHARLS JEYAKUMAR 61/M 560390C IW+RV YES STK + + - - 
DEVAN 63/M 346793D AWMI YES STK - + - + 
SUNDHARAMOORTHY 70/M 346851D AWMI YES STK + - - + 
MURUGESAN 43/M 350107D AWMI YES STK + - - + 
SELVAM 40/M 350563D AWMI NO - + - - + 
HAJEE HAN 43/M 352003D ASMI NO - - - + + 
RAVI 40/M 352113D ASMI YES STK - - - + 
MURUGESAN 75/M 352131D AWMI NO - - - + + 
KUPPASWAMY 56/M 352098D IW+RV NO - + + - - 
JAYASANKAR 38/M 352145D AWMI NO - - - - + 
RAJA 28/M 352511D AWMI YES STK - - - - 
BALAKRISHNAN 49/M 352738D AWMI YES STK - - - + 
JANSKRISNAN 64/M 353577D IW+RV+PW YES STK - - - - 
RAJA SELVA 34/M 352155D ASMI YES STK - - - + 
RAJA  53/M 353609D IWMI NO - - - + + 
PURUSOTHAMAM 55/M 352179D IW+PW YES STK - - + - 
PUSHPA RANI 60/F 326005D AWMI YES STK - + - - 
JAGAN RAJAK 57/M 337169D IW+PW NO - + - + - 
NATESAN 85/M 355212D IW+RV YES STK + - - - 
KANNIYAPPAN 56/M 355238D IW+RV+PW YES STK - + + - 
SOUNDAR RAJAN 55/M 355248D IW+RV YES STK + + + - 
RAMANA 55/M 357664D IW+RV YES STK - - - + 
JAYARAMAN 70/M 359059D AWMI YES STK + + - + 
JANAKIRAMAN 58/M 358237D AWMI YES STK - - - - 
SHYMOL ROY 54/M 204728D IWMI YES STK - + + + 
JAYARAMAN 55/M 359087D IW+LW+PW YES STK - - - + 
SHANMUGAM 54/M 359105D AWMI NO - - + - - 
SHEK KASIM 58/M 757069B AWMI YES STK - + + - 
RAMACHANDRAN 81/M 359101D LW+PW NO - - - + + 
AMEER JAN 50/M 359164D AWMI NO - + - - + 
THOMAS GANAEKARAN 49/M 359097D ASMI NO - + + + - 
GOPAL 70/M 359187D LW+PWMI YES STK + + - - 
NAVANEETHAM 60/F 361165D IW+RV+PW YES STK + - + - 
PAVALAMMAL 65/F 363033D IW+RV+PW YES STK + + - _ 
RANGAN 56/M 363038D ASMI YES STK + - - + 
MICHEL 53/M 363051D AWMI YES STK + + - - 
KUMAR K 46/M 363057D IW+RV YES STK - - + - 
PANGAJAN 65/M 360300D IW+RV YES STK + - - - 
SHANMUGAM 46/M 360741D LWMI NO  - - + + 
RAFI 37/M 971053C PW+RV YES STK - + + - 
RAMACHANDRAN 72/M 189961B ASMI YES STK + + - + 
MUNISAMY 57/M 363782D IW+PW YES STK - + + + 
THANGAVELU 70/M 363077D IW+RV YES STK - + + + 
SEKAR 59/M 189826D IW+RV+PW YES STK - - + + 
DECEMBER 2008          
 
NAME A/S H.NO MI LYSED AGENT DM HTN Dys SMK 
PALANI 56/M 368048D IW+RV+PW YES STK - - - + 
MOHAN 55/M 893280C IW+RV YES STK + + + - 
KRISHNAN 75/M 363174D AWMI YES STK + + - - 
RAMAMURTHY 58/M 363194D IW+RV+PW YES STK + + - + 
RAVI 40/M 365088D HLMI YES STK + + - - 
KUPPUSWAMY 75/M 753392C ASMI YES STK - - - + 
JAYALAKSHMIAMMAL 71/F 365145D AWMI YES STK + - + - 
VALLIAMMAL 65/F 365157D AWMI YES STK + + - - 
THIYAGARAJAN 52/M 630456C AWMI YES STK + + - - 
BOOPALAN 59/M 365162D ASMI YES STK - + - + 
DAMODARAN 59/M 367109D AWMI YES STK + +  + 
ILYAS AHMED 52/M 365609D AWMI YES STK - - + + 
KANAGASABHA 57/M 368064D AWMI YES STK - - + + 
DHAMOTHARAN 71/M 368067D IWMI YES STK + - + + 
MALAR 36/M 368061D AWMI NO  - - + - 
SYED SALAUDDIN 56/M 367747D AWMI YES STK - - - + 
DURAI RAJ 58/M 367837D AWMI YES STK + + - - 
KRISHNAMOORTHY 65/M 363136D IW+RV+PW YES STK + + - + 
SYED NOOR S 70/M 368165D AWMI YES STK + + - + 
GOVINDAN 53/M 368214D ASMI YES STK + + - - 
SANTHOSAM 65/M 368212D ASMI NO  - + - + 
MOORTHY 54/M 368218D IWMI YES STK + + + - 
AYUB ALI KHAN 46/M 368238D IWMI NO  + - - + 
PONNUSWAMY 61/M 368265D AWMI YES STK - - + + 
ETHIRAJN 63/M 370826D ASMI YES STK - - - - 
LAKSHMANAN 52/M 248898C IW+RV+PW YES STK + - - - 
KANTHAMMAL 60/F 371072D LW+PW YES STK + - - - 
KARUNAKARAN 50/M 371071D AWMI YES STK - + - - 
ALIMA BEE 70/F 371091D IWMI YES STK + + - - 
DURAI SAMY 70/M 371122D AWMI YES STK - - - + 
SIVALINGA ACHARI 57/M 371128D ASMI NO - - + + - 
SAMU 58/M 372533D AWMI YES STK - - + + 
BALAMURUGAN 35/M 372524D IW+RV+PW YES STK + + - + 
GOVINDAMMAL 70/F 370956D AWMI NO - - - + - 
VEDI 55/M 372620D AWMI YES STK + + - - 
KANAGAMMAL 70/F 372627D AWMI YES STK + + + - 
RAGURAMAN 30/M 372647D IWMI YES STK - + + + 
SRINIVASAN 45/M 258630D IWMI YES STK - + - + 
MADHUSUDAN  60/M 364900D AWMI YES STK - + - + 
NANDAN 49/M 372738D IW+RV NO - - - - + 
NARASIMALU 62/M 372747D IW+RV+PW YES STK + + + - 
SHANMUGAM 73/M 844769B AWMI YES STK + + - - 
DURAI RAJAN 48/M 485124C IWMI NO - + + - - 
CHANDRASEKARAN 44/M 375073D IW+RV YES STK - + + - 
ANANDA 52/M 375090D AWMI YES STK + + + + 
SAORI AMMAL 75/F 376438D IW+PW NO - + + - - 
MAQBOOLAHMED 56/M 375150D HLWMI YES STK + + + + 
GOVINDRAJ 61/M 375168D AWMI YES STK + - - + 
MUTHU 57/M 377064D IW+LW+PW YES STK - - + + 
DEVAKI 40/F 377075D AWMI NO - + + - - 
VILVANATHAN 76/M 377104D IW+RV+PW YES STK - - - + 
RAMALINGAM 67/M 548639A IWMI NO - + - - + 
DAYALAN 32/M 377114D AWMI YES STK - - + - 
SAROJA 53/F 376987D IW+ RV+PW YES STK + - - - 
KAMALAMMAL 55/F 377718D AWMI NO - + + + - 
SATHYANATHAN 59/M 378342D IW+PW YES STK - + + + 
ELANGOVAN 70/M 378599D IW+PW+RV YES STK - - - - 
KANNAN 63/M 378782D ASMI YES STK   + + 
PANDIAN 51/M 380092D ASMI YES STK + + + - 
ANANDARAJ 55/M 378793D IW+RV YES STK + + + + 
GANDHI 51/M 264557B HLMI YES STK - - - + 
ANNAMALAI 50/M 117119B AWMI YES STK + - + + 
RAGU 45/M 378673D IW+RV YES STK - + - + 
JAN 2009          
 
NAME A/S H.NO MI LYSED AGENT DM HTN - SMOK 
Rukmani 45/F 382590D IW+PW YES STK + + + - 
Krishnan 64/M 382622D IW+RV YES STK _ _ - + 
Kesavareddy 59/M 382636D AWMI YES STK + + - + 
Abdulrehman 68/M 382735D AWMI YES STK + + - - 
Vasantha 66/f 910513D IW+RV TES STK + + - - 
Indrani 55/F 217092B AWMI YES STK + - + - 
Santhaban 51/M 382795D AWMI YES STK + - - + 
Gobindraj 75/m 385407D IW+RV YES STK - + - - 
Gnanambal 64/F 378591D AWMI YES STK + - - - 
Maqbool 67/M 385435D AWMI YES STK + + + - 
Arumugam 57/m 537133b AWMI YES STK - - + + 
Murgesan 59/M 802859B AWMI YES STK + + + - 
Ramaswami 71/M 386883D AWMI YES STK + + + + 
Murugesan 85/m 387082D IW+RV YES STK + - - + 
Mohan velu 62/m 016388D RV+IW YES STK + + - + 
Durai s 55/m 387123D AWMI YES STK + + - - 
Ambuja 35/F 387141D IW+RV YES STK + - + - 
Denan g 60/m 623533C AWMI TES STK + + + - 
Milton a 38/M 387217D IW+RV YES STK - - + - 
CHRISTOPHER 48/M 387247D ASWMI YES STK - - - - 
NARESH 52/M 390098D AWMI YES STK + + + - 
AMMAIMMAL 65/F 390113D IW+RV+PW YES STK + + - - 
VELLAI 65/M 392129D AWMI YES STK + - + + 
MURUGAN 33/M 391205D AWMI YES STK - - - + 
FAKIR 42/M 392596D ASWMI YES STK - - - + 
MOHANAMMLA 56/F 392465D IW+PW YES STK + + + - 
JAYALAKSHMI 78/F 392279D IW+RV YES STK - - + - 
KAMRAJ 43/M 265938D AWMI YES STK - - - - 
ROJA BAI 65/F 392293D AWMI YES STK + + - - 
KANNAN 68/M 393544D IW+RV YES STK + - + - 
BALU 27/M 395022D AWMI YES STK + - + + 
TULASINATHAN 46/M 395039D IW+RV+PW YES STK - - - - 
SIVANANDAN 68/M 512318C ASWMI YES STK - - + - 
PUSPAWATHI 70/F 395132D AWMI YES STK - - - - 
MUNNI SAMY 71/M 395146D IWMI YES STK + + + + 
MOHANAMMAL 56/F 392465D IW+RV+PW YES STK + + + - 
JAGADAMBAL 62/F 395290D IW+RV YES STK - + - - 
GANESAN 71/M 156014C AWMI YES STK   -  
THANGO 55/M 331515D AWMI YES STK - - - - 
GOPALSWAMI 60/M 698896D IW+PW+RV YES STK + + + + 
JAYALAKSHMI 56/F 398929D IWMI YES STK - - - - 
VASUGIL 64/F  AWMI NO - - - - - 
MUNISWAMY 71/M  IW+RV NO - + + + + 
SRINIVASAN 55/M  AWMI NO - + + + + 
MAHABABUNISHA 70/F  ASMI NO - + + - + 
AMEER BEE 60/F  AWMI NO - - - + - 
ELANGOVAN 33/M  AWMI NO - + + - + 
IRUDAYANATHAN 63/M 382601D IW+RV+PW YES TNK - - + + 
SIVANANDAM 67/M 512318C AWMI YES TNK + - - - 
GOUSE BASHA 48/M 387075D IW+RV YES TNK - - - + 
ATHIMUULAM 60/M 392267D IW+RV YES TNK - + - + 
SRINIVASAN 75/M 266122D AWMI YES TNK + - + + 
KANNAYIRAM 62/M 395072D IW+PW+RV YES TNK + + - + 
ASMATHUNISA 69/F  IW+PW+RV YES TNK + + + - 
FEB 2009        +  
 
NAME A/S H.N MI LYSED AGENT DM HTN - SMOK 
MANIAMMAL 51/F 400121D AWMI YES STK + - + - 
DURAI 70/M 399143D IWMI YES STK + + + + 
KANNAN M 67/M 400244D AWMI YES STK + - + + 
GOPALAN 64/M 040628D IW+RV YES STK + - - _ 
MUNIRAGULU 62/M 400275D IW+RV YES STK + + + + 
JOTHI G 63/M 367566B IW+RV YES STK + - - - 
JEEVA 80/M 401936D IW+RV YES STK + + - + 
SUBRAMANI 74/M 400413D AWMI YES STK + + + - 
DORAIRAJ 67/M 208594D AWMI YES STK + + - + 
OMPRAKESH 45/M 408078D AWMI YES STK + + - - 
NEOPOLIAN 41/M 410007D AWMI YES STK - - - + 
PANJAMMAL 57/F 408999D IWMI YES STK - + -  
DURAISAMY 65/M 402980D IW+PW+RV YES STK - + + + 
VINAYAGAM 48/M 411280D AWMI YES STK + + - - 
PADAVATTAN 60/M 412021D IW+PW+RV YES STK - - - + 
SIMON 40/M 862094C IW+PW+RV YES STK - + - - 
ROSUL 61/M 412043D IW+PW+RV YES STK - -  - 
SUBRAMANI 47/M 412117D AWMI YES STK - - + - 
NEELA 52/M 413114D AWMI YES STK - + + - 
LAKMI 66/M 412170D IW+RV YES STK + + + - 
MALARKADAI 50/F 412227D IW+PW YES STK + - + - 
RAVI KUMAR 44/M 354960B LW YES STK + + + - 
DEVARAM 35/M 415041D AWMI YES STK + + + - 
KRISHNAMOORTY 80/M 227759C AWMI NO - + + - - 
PARKODI 55/M 403190D AWMI NO - + - - + 
POGATHAN 55/M 400465D AWMI NO - + + - - 
ABBOGASAN 60/M 404935D IW+RV NO - + + - - 
CHINNAGREYAN 70/M 408038D IWMI NO - + + + - 
PAPPAMAL 78/M 998969B ASMI N0 - + + - - 
KANNAN 47/M 412058D AWMI NO - + - + + 
MD IQBAL 64/M 412128D ASMI NO - - - - - 
KARNAKARAN 54/M 412149D ASMI NO - - + - - 
RATHABAI 65/M 412206D IWMI NO - - + - + 
NAGARANI 50/F 415259D AWMI NO - + + - - 
RIYAZ AHMED 40/M 415892D AWMI NO - - - - + 
SUBBURAJ 56/M 400111D IW+RV YES TNK - + - - 
JAYARAJAYAN 60/M 400192 AWMI YES TNK + - + + 
ANJANEYOLIN 52/M 417705D LWMI YES TNK + + + - 
GANANA  71/M 400214D IW+PW+RV YES TNK + - - - 
PADMAVATHI 83/M 400239D AWMI YES TNK - - + - 
JAGADAMAN 69/M 266040D AWMI YES TNK + + - - 
SARASWATHI 51/F 406697D AWMI YES TNK - - + - 
SANTHAM 56/M 157324D AWMI YES TNK + - + + 
SANTHA 62/F 408073D AWMI YES TNK + + - - 
NATARAJAN 61/M 408155D AWMI YES TNK + - - - 
GAJCHAKSHAM 68/F 415014D AWMI YES TNK - + - - 
DAMODARAN 60/M 367109D AWMI YES STK + - + + 
KUPPARI 50/M 415091D AWMI YES STK + + - - 
SABIR 50/M 417629D AWMI YES STK + + - - 
PURSOTTAMAM 58/M 417646D AWMI YES STK + + + - 
KASPUNISHA 50/F 417671D IW+RV+PW YES STK + - + - 
KRISHANAN 67/M 745703C IW+RV+PW YES STK + + - + 
MANOHARI 55/F 417772D IW+RV+PW YES STK + + + - 
MARCH 2009 
 
         
NAME A/S H.N. MI LYSED AGENT DM HTN DYS SMK 
SELVA 47/M 186293D IW+RV+PW YES STK + + - + 
KALYANI 75/F 417377D AWMI YES STK + + + - 
LEEMAMMAL 60/F 418899D AWMI YES STK + - - - 
JABARANI 54/F 419098D ASMI YES STK - - - - 
ARUMUGAM 55/M 419162D AWMI YES STK - + - - 
SUBRAMANIUM 47/M 420669D ASMI YES STK - + + + 
ISMAIL 52/M 420809D ASMI YES STK + + - - 
RAJENDRAN 47/M 420897D AWMI YES STK - - + - 
RAJENDRAN 42/M 402850D AWMI YES STK - + + - 
KHALEELUR 54/M 422535D IW+PW YES STK - + - - 
DEIRVU 78/M 422167D PW+RV YES STK - + + + 
GANGADHARAN 56/M 422193D IW+PW YES STK - + + - 
RAMAMURTHY 47/M 423256D AWMI YES STK + - + - 
VENKATESAN 64/M 423308D AWMI YES STK + - - + 
DAMODARAN 68/M 423817D AWMI YES STK + + + + 
GOVIND RAJ 59/M 424115D IW+RV YES STK + + - + 
KRISHNASWAMY 80/M 424185D AWMI YES STK + + - - 
JOSEPH 48/M 423372D IWMI YES STK + - + - 
DEVARAJ 48/M 425404D IW+PW YES STK + + - - 
KHALEED 55/M 426171D ASMI YES STK + + - - 
SUBRAMANI 59/M 429004D AWMI YES STK + + - - 
LAKSHMI 50/F 475812C IWMI YES STK + + - - 
SARASWATI 58/F 429034D AWMI YES STK + - + - 
VENKATACHALAM 60/M 428007D AWMI YES STK - - - + 
ELUMALI 62/M 407126D AWMI YES STK - + - +- 
SRINIVASAN 61/M 431591D IW+RV YES STK - + - - 
KAMALNATHAN 44/M 432352D AWMI YES STK + +  + 
SELVAM 65/M 432035D IW+PW+LW YES STK - - + + 
SELVA RAJAN 59/M 432070D IW+ASMI YES STK - + - - 
MURALI 51/M 322655D AWMI YES STK + + - - 
SAMUEL 50/M 432122D AWMI YES STK + + - + 
SELVAM 37/M 432124D IW+RV+PW YES STK + + - - 
KUMAR 44/M 432146D PW+LW YES STK - - - - 
DAMODARAN 45/M 295455D ASMI YES STK + - - - 
NAGARAJAN 55/M 432185D IW+AWMI YES STK - + - - 
JIBASING 41/M 432188D IWMI YES STK + + - + 
LAKSHMI 65/M 432217 ASMI YES STK + + - - 
RAMESH 40/M 434934D AWMI YES STK + - + - 
VELAGUDAN 61/M 415175D ASMI YES STK - + - + 
JAGANNATHAN 36/M 432233D AWMI YES STK + + + + 
SANTHANAM 51/M 382795D AWMI NO - + + - + 
PALANISWAMY 48/M 417652D AWMI NO - + + - - 
RANI 56/F 207496D AWMI NO - + - - - 
MUNIRAGULU 70/M 419001D IWMI NO - + - - - 
MURUGESAN 60/M 419018D IWMI NO - + + - - 
JEBARANI 54/F 419098D AWMI NO - + + - - 
ABDUL HAJ 68/M 702476C AWMI NO - + + + - 
SATHYAMOORTHY 58/M 423473D IWMI NO - + - + - 
AKBER ALI 70/M 426160D IWMI NO - + + - + 
PALANI 66/M 998658B AWMI NO - - + + +- 
PARASURAMAN 65/M 428071D AWMI NO - - + - - 
KARUNAKARAN 40/M 394052D AWMI NO - - + + + 
CHANDAN 64/M 429207D IW+RV+PW YES TNK + - + + 
APR 2009        - - 
LAKSHMI 51/F 435867d IW+RV YES STK + + - - 
RAMAMOORTHY 67/M 436093D AWMI YES STK + + - + 
KESAVEL 65/M 436106D AWMI YRS STK + + + - 
LAKSHMI 65/F 432217D AWMI YES STK + - - - 
RAGUNATHAN 46/M 439158D ALWMI YES STK - + - + 
SAYED NASEER 46/M 439184D AWMI YES STK - _ - - 
SAMPATH 44/M 439173D HLMI YES STK - + - - 
NATARAJAN 63/M 818602B AWMI YES STK - - - + 
ILLIAC 42/M 757968C AWMI YES STK + + + - 
ELUMALAI 48/M 441085D AWMI YES STK + + + - 
MANOHARAN 52/M 441072D IW+RV+PW YES STK + + + - 
SREENIVASAN 36/M 441124D AWMI YES STK + + + - 
RAVI 45/M 441121D ASWMI YES STK - + - + 
ABUNI 61/M 441140D ASWMI YES STK - - + - 
ILAMPARWATHI 49/M 067342D IW+RV YES STK - - + - 
MUNNIAMMAL 60/F 443060D IWMI YES STK + - + - 
SUNDARAJAN 49/M 013170A ASWMI YES STK + - - - 
KUMARESAN 51/M 443811D AWMI YES STK - - + + 
SATNEYA 47/M 444065D AWMI YES STK - - + - 
SOWKATH ALI 39/M 444068D IW+RV YES STK - - - + 
MUNGESAN 65/M 444087D ASWMI YES STK + +- - + 
MOHAN 51/M 445747D ASWMI YES STK + + + - 
SRINIWASAN 40/M 446333D IWMI YES STK - + + - 
DHAKSHINA 56/M 446373D AW+IW YES STK + + + - 
ARUMUGAM 49/M 446891D IW+RV+PW YES STK + + + + 
SHANMUGAM 50/M 447770D AWMI YES STK + + - + 
JAYARAMAN 75/M 447920D AWMI YES STK - + - - 
PACHIAPPAN 76/M 449013D HLMI YES STK + + - + 
NAVNEETHAMAL 65/F 449041D AWMI YES STK + - + - 
ARJEL 55/M 449069D IW+RV YES STK - - + + 
SHANTHA 55/M 449179D IW+RV+LM YES STK - + + - 
KAMLA BAI 69/F 450648D AWMI YES STK - + - - 
KRISHNAMURTHY 54/M 449272D IW+RV YES STK - _ - - 
KASTHURIAMMAL 65/F 452334D AWMI YES STK - + - - 
JAGADAMBAL 62/M 395290D AWMI YES STK - - - + 
MAWEAPPAN 67/M 432034D AWMI NO - + + + - 
VENKATESAN 33/M 432064D ASMI NO - + + + - 
NIYAZ 42/M 129225B IW+RV+LW NO - + + + - 
GUNASEKARAN 40/M 008203D HLMI NO - + + + - 
VENU 60/M 446332D ASMI NO - - + - + 
JAYARAMAN 40/M 446334D AW+IW NO - - - + - 
RATHAKONKAN 86/M 447164D IW+RV+PW NO - - - + - 
BALU K. 47/M 446405D AWMI NO - + - + - 
PERUMAL 55/M 449025D IW+RV+PW NO - + - - - 
ABDUL JABBAR 60/M 449053D IWMI NO - - - + + 
SENTHIL 30/M 450087D AWMI NO - - - + - 
SANKARAN 63/M 014313C IW+RV YES TNK - - - + 
LAKSHMI 65/F 432217D AWMI YES TNK + +- - + 
SADAWANTHAM 48/M 932104C IWMI YES TNK + + + - 
JAGADAMBAL 62/F 395290D AWMI YES TNK - + + - 
MAY 2009          
NANE A/S HN MI LYSED AGENT DM HTN DYS SMK 
MANOHARAN 50/M 452543D AWMI YES STK + + - + 
LAKSHMI 45/F 452607D IWMI YES STK - + - - 
LAKSHMANAN 62/M 452438D IWMI YES STK + + - + 
PONNURANGAM 65/M 452675D IWMI YES STK + - + + 
KALAI 52/M 454555D IWMI YES STK - - + + 
ADULSALOAN 80/M 454609D AWMI YES STK - + + - 
JAGAVEL 59/M 449137D AWMI YES STK - + - + 
LATITHAMMAL 54/M 454755D IW+RV=PW YES STK - _ - - 
VALLIMABEL 65/F 454759D AWMI YES STK - + - - 
SAMPOORNAMMA 65/M 390880C IWMI YES STK - - - + 
JOHN SELVARAJ 37/M 457031D IW+RV+PW YES STK + + + - 
BALAJI 36/M 318291B ASMI YES STK + + + - 
NEELA KUNDAN 58/M 460016D ASMI YES STK + + + - 
VELAYA KUMAR 53/M 460016D AWMI YES STK + + + - 
SRINIVASAN 44/M 460026D LWMI YES STK - + - + 
ANNAWAMY 71/M 460050D IWMI YES STK - - + - 
MURUGAN 60/M 440056D IW+RV YES STK - + - + 
JYOTHI 59/F 590601B ASMI YES STK - _ - - 
SHANKARAN 72/M 460193D AWMI YES STK - + - - 
VELUMANI 60/F 48152D IW+RV YES STK - - - - 
HALUMABEE 65/F 988061C IW+RV YES STK + + + - 
MARGABAVELLU 70/M 461729D ASMI YES STK + + + - 
SARASWATHI 52/F 454623D AWMI YES STK + + + - 
SADIQ 38/M 463382D IWMI YES STK + + + - 
KRISHNAN 60/M 463478D AWMI YES STK - + - + 
MUNIATHAN 60/M 464554D AWMI YES STK - - + - 
MOHANAN 58/M 465583D ASMI YES STK - - + - 
MUNNISWAMY 70/M 475580D IW+LW+PW YES STK + - + - 
RADHAKRISHNAN 58/M 465650D ASMI YES STK + - - - 
AMEENA 49/F 467842D AWMI YES STK - - + - 
KAMRAJ 40/M 469538D IW+RV YES STK - - + - 
DAYALAN 50/M 469566D AWMI YES STK - - - + 
NITHYANANDAN 42/M 469574D AWMI YES STK + +- - + 
MURALIKRISNAN 49/M 469680D AWMI YES STK + + + - 
RAJI 37/M 469055D IW+RV YES STK - + + - 
RAJENDRA  BABU 50/M 453245D ASMI NO - + + + - 
ABDUL BASHA 50/M 454595D IW+RV NO - + + + + 
BAKHTAVACHALAN 59/M 457047D IW+LW+PW NO - + + - + 
VIMLA 65/F 458026D ASMI NO - - + - - 
PRITHUBI 60/M 460012D IWMI NO - + + - + 
ARUMUGAM 60/M 460072D AWMI NO - + - + + 
JAYALAKSHMI 80/F 461542D AWMI NO - - - + - 
AZOORA BEGUM 60/F 427537C AWMI NO - - + + - 
AMEENA 49/F 467842D AWMI NO - - + - - 
RAMAMOORTHY 68/M 469614D AWMI NO - - _ - - 
MAHADEVAN 55/M 460005D IW+RV+PW YES TNK - + - - 
JUNE 2009          
NAME A/S H.N MI LYSED AGENT DM HTN DYS SMK 
CHINNAKULANTHI 75/F 469551D AWMI YES STK + + + - 
BARANI 51/M 277187C IW+RV YES STK + + + - 
ALLABAGESH 60/M 352026D AWMI YES STK + + + - 
ARUMUGAM 65/M 472172D ASMI YES STK - + - + 
RAJAMMA 60/F 120207C AWMI YES STK - - + - 
VENKATESAN 55/M 470918D AWMI YES STK - - + - 
PADMAWATHI 68/F 476703D ASMI YES STK + - + - 
SAMPATH RAJ 50/M 478548D IW+PW YES STK + - - - 
DAKSHNAMURTHY 61/M 397446D ASMI YES STK - - + + 
CHOKAMMAL 76/F 480209D IW+PW YES STK - - + - 
KAMAL BASHA 57/M 480214D IWMI YES STK - - - + 
KHADEER AHMAD 45/M 480223D AWMI YES STK + +- - + 
JAYARAMAN 56/M 980256D IWMI YES STK + + + - 
DUKSHAN 36/M 480287D IWMI YES STK - + + - 
ESACK 40/M 480428D AWMI YES STK + + + - 
RAVICHANDRAN 48/M 480495D AWMI YES STK + + + + 
SHANMUGAM 70/M 480306D IWMI YES STK + + - + 
VEERSWAMY 50/M 480316D IW+RV YES STK - + - - 
VENUGOPAL 65/M 480312D IWMI YES STK + + - + 
SONU 50/F 480352D AWMI YES STK + - + - 
SAGADERAN 65/M 482884D AWMI YES STK - - + + 
IQBAL 26/M 483704D AWMI YES STK - + + - 
RAVISHANKER 50/M 480312D IWMI YES STK - + - + 
MUTHUKRISHNAN 65/M 483114D AWMI YES STK - _ - - 
VIJAYAN 40/M 484142D AWMI YES STK - + - - 
SARASWATHY 65/F 484185D AWMI YES STK - - - - 
JEEVA 50/F 484259D AWMI YES STK + + + - 
SALIMA 55/F 486624D IW+RV YES STK + + + - 
DESAB REDDY 65/M 486660D IWMI YES STK + + + - 
NARAYAN SWAMY 75/M 608766D IW+RV YES STK + + + - 
GOVINDSWAMY 65/M 490126D IW+RV YES STK - + - + 
LAKSHMI 58/F 490197D IW+RV YES STK - - + - 
RASOO LKHAN 50/M 053465B AWMI YES STK - + - + 
JOTHISEKHAR 37/M 882437C AWMI YES STK - _ - - 
CHOKAAMMAL 78/F 480209D IWMI NO - - + - - 
GEETHA LAKSHMI 55/F 312919D AWMI NO - - - - - 
MALIYA 55/F 312942D AWMI NO - + + + - 
SEIKHHERDEU 85/M 486633D IW+RV+PW NO - + + + - 
KANTHA 58/F 486163D AWMI NO - + + + - 
VELU M 72/M 480295D IW+RV+PW YES TNK + + + - 
MANOHARAN 53/M 441072D AWMI YES TNK - + - + 
JAYARAMAN 70/M 700917B IW+PW+RV YES TNK - - + - 
          
JULY 2009 
 
     
    
          
NAME A/S H.N MI LYSED AGENT DM HTN DYS SMK 
ZUBEDHA BEGUM 73/F 490283D AWMI YES STK - - + - 
LAKSHMI 50/F 493289D AWMI YES STK - - + - 
MASILAMANI 52/M 493028D AWMI YES STK - - - + 
SUSHILA 62/F 493089D AWMI YES STK + +- - - 
ABDUL AZEEZ 40/M 497965D AWMI YES STK + + + - 
DURAI RAJ 50/M 497971D AWMI YES STK - + + - 
GANESAN 50/M 497977D AWMI YES STK + + + - 
SUNDER RAJAN 48/M 500508D AWMI YES STK + + + + 
JAIYAMMAL 75/F 500570D AWMI YES STK + + - - 
ANBALAGAN 45/M 495245D HLWMI YES STK - + - - 
AMBU 36/M 493437D IWMI YES STK + + - + 
RAMALINGAM 65/M 493463D AWMI YES STK + - + + 
DAKSHNAMOORTHY 47/M 493531D AWMI YES STK - - + + 
SHANTI 47/M 493540D IW+RV+PW YES STK - + + - 
KUMAR 46/M 223247C RV+IW YES STK - + - + 
MD JABAL 59/M 500626D AWMI YES STK - _ - - 
GUARDASWAMY 83/M 503570D IWMI YES STK - + - - 
SAEED BASHA 78/M 965742C IW+PW+RV YES STK - - - + 
JAYASEELAN 52/M 149481D AWMI YES STK + + + - 
SEEVAGAMI 65/F 508040D AWMI YES STK + + + - 
RANDURAH 68/M 508132D IW+RV+PW YES STK + + + - 
BABU 40/M 508171D IW+RV YES STK + + + - 
ZEHATHA BEGUM 52/F 508097D IW+RV+PW YES STK - + - + 
PREMA 62/F 8555125C IW+RV YES STK - - + - 
BALAKRISHNAN 60/M 511154D ASMI YES STK - - + - 
MUNIAMMAL 65/F 508376D AWMI YES STK + - + - 
LAKSHMI 50/F 493289D AWMI NO - + - - - 
PANDURANGAN 71/M 341630D AWMI NO - - - + + 
RAMACHANDRAN 58/M 120464B IW+RV+PW NO - - - + - 
INANYAIAMALAI 59/M 505557D LWMI NO - - - - + 
MURALINATHAN 42/M 505676D AWMI NO - + +- - + 
JAYCHAND 62/M 488168D AWMI YES TNK + + + - 
SAMBANDA MURTHY 59/M 493449D AWMI YES TNK - + + - 
GOBEL ANDREWS 47/M 501436D AWMI YES TNK + + + - 
PANDIAN 50/M 508303D AWMI YES TNK + + + + 
RAMDAS 60/M 514101D AWMI YES TNK + + - + 
AUGUST 2009 
 
     
    
NAME A/S H.N MI LYSED AGENT DM HTN DYS SMK 
BAIRANAN 42/M 514263D IW+RV+PW YES STK + - + + 
MANIK BASHA 79/M 514284D AWMI YES STK - - + + 
SAROJA 45/F 514294D AWMI YES STK - + + - 
VARDIAH 65/M 513695D AWMI YES STK - + - + 
SHANMUGANATHAN 28/M 508443D AWMI YES STK - _ - - 
ELEANHARAN 50/M 508461D IW+PW YES STK - + - - 
MANI 45/M 517141D IW+RV YES STK - - - + 
KALM 30/M 518015D AWMI YES STK + + + - 
PANGULAE 70/M 518017D AWMI YES STK + + + - 
ANANDAN Y 53/M 518292D ASMI YES STK + + + - 
DAYAWATI 55/M 518557D AWMI YES STK + + + - 
SYEED FAROOK 49/M 518620D AWMI YES STK - + - + 
SHREN KUMAR 56/M 518632D AWMI YES STK - - + - 
SHANKAR 42/M 526113D AWMI YES STK - + - + 
SUDARSHAN 55/M 526737D AWMI YES STK - _ - - 
JULEUS 59/M 289227C AWMI YES STK - + - - 
SENTHAMERI 59/F 526271D AWMI YES STK - - - + 
LOGAMMAL 75/F 526309D AWMI YES STK + + + - 
LAKSHMI DEVI 53/F 326345D AWMI YES STK + + + - 
NARAYANAN 55/M 526351D IW+LW YES STK + + + - 
BARUN KANTI 67/M 141053D AWMI YES STK + + + - 
ELAVA HAJU 45/M 530059D IW+RV YES STK - + - + 
SURYAKANTHA 71/F 530054d IW+RV+PW YES STK - - + - 
KRISHNAN 54/M 530063D AWMI YES STK - - + - 
CHANDIRAN 59/M 530174D IW+RV YES STK + - + - 
KANDASWAMY 47/M 530321D AWMI YES STK + - - - 
NARGARAJA 68/M 514429D AWMI NO - - - + + 
KALYANAMMA 75/F 518006D IW+RV NO - - - + - 
GOVINDASWAMY 70/M 518637D ASMI NO - - - - + 
DEVARAGULU 60/M 518755D ASMI NO - + +- - + 
KANNIYAPPAN 70/M 219446D AWMI NO - + + + - 
SUMATHI 41/F 526400D AWMI NO - - + + - 
NATARAJAN 65/M 530051D AWMI NO - + + + - 
SASIKALA 53/F 117540D ASMI NO - + + + + 
CHINNASWAMY 75/M 395861D AWMI YES TNK + + - + 
ARJUNAN 78/M 526333D IW+RV YES TNK - + - - 
SEPTEMBER 2009 
 
     
    
NAME A/S H.I MI LYSED AGENT DM HTN DYS SMK 
MUTHUKARUPPAN 59/M 530402D AWMI YES STK - - + + 
DEVARAJ 60/M 472093C AWMI YES STK - + + - 
DHANNAMAL 37/F 543047D AWMI YES STK - + - - 
VENKATARAMAN 40/M 534853D IW+RV+PW YES STK - _ - - 
NAGARAJAN 67/M 535088D IW+RV YES STK - + - - 
PANDURANJAN 65/M 535102D AWMI YES STK - - - - 
RANDHAMMAL 60/F 535111D IW+RV+PW YES STK + + + - 
GANESHAN 51/M 536934D AWMI YES STK + + + - 
BALARAM 53/M 536861D AWMI YES STK + + + - 
GNANU KUMAR 57/M 526403C IW+RV YES STK + + + - 
MARGABANDHU 51/M 535252D AWMI YES STK - + - + 
JOHN 49/M 535254D IW+RV YES STK - - + - 
DAYANANDAN 59/M 218691A AWMI YES STK - - + - 
SASIKALA 37/F 535438D  AWMI YES STK + - + - 
VANNAMALAI 59/F 307305D IW+RV YES STK + - - - 
DEBABRATH 59/M 537687D IW+RV YES STK - - + + 
ABDUL BASHEER 51/M 540051D IW+RV YES STK - - + - 
GEETHA 56/F 734160C IW+RV YES STK - - - - 
ARSADS SEELAM 63/M 864517B IW+RV YES STK + +- - + 
DHARANI 47/F 540204D IW+PW YES STK + + + - 
BABU 37/M 640758D AWMI YES STK - + + - 
AMRASAL  58/M 541705D AWMI YES STK + + + - 
SRINIVASAN 57/M 544138D IW+RV YES STK + + + + 
MURALI 37/M 544139D IW+RV YES STK + + - + 
MUNAF 61/M 540266D IW+RV YES STK - + - - 
LAKSHMANAN 70/M 544371D AWMI YES STK + + - + 
GANESAN 70/M 544376D AWMI YES STK + - + + 
VIJAYAN 65/M 545387D AWMI YES STK - - + + 
MUNUSWAMY 70/M 544448D AWMI YES STK - + + - 
RAZAMA BEE 85/F 546296D IW+RV YES STK - + - - 
CHANCHALA 60/F 544006D IW+RV YES STK - _ - - 
KULANDAI 55/M 535138D IW+RV NO - - + - - 
SHANTHI 60/F 544036D AWMI NO - - - - + 
SIVAJI 40/M 544076D ALMI NO - + + + - 
SUBRAMANIUM 65/M 549373D IW+RV NO - + + + - 
SURESH KUMAR 47/M 540170D ASMI NO - + + + - 
JEYACHANDRAN 50/M 554332D AWMI NO - + + + - 
CHINNAKANNA 90/M 544158D IWMI NO - - + - + 
VENUGOPAL 47/M 533115D IW+RV YES TNK - - + - 
GOPAL NAIDU 62/M 539520D AWMI YES TNK - + - + 
SHANKER 50/M 544432D AWMI YES TNK - _ - - 
SRINIVASAN 73/M 266122D AWMI YES TNK - + - - 
VELUMANI 61/F 461521D IW+RV YES TNK - - - - 
OCTOBER 2009 
 
     
    
NAME A/S H.N MI LYSED AGENT DM HTN DYS SMK- 
SASHI KUMAR 31/M 549389D AWMI YES STK + + + - 
DURAI 75/M 549593D AWMI YES STK + + + - 
KAMALAKANNAN 35/M 549398D AWMI YES STK - + - + 
SUNDARAJAN 52/M 549394D AWMI YES STK - - + - 
NARAYAN SWAMY 62/M 330903C AWMI YES STK - - + - 
PANDYA RAJAN 73/M 557962D AWMI YES STK + - + - 
BABAN 53/M 554004D IWMI YES STK + - - - 
RAJINDRAN 55/M 554014D AWMI YES STK - - + + 
KANNIYAPPAN 60/M 079028C AWMI YES STK - - + - 
AKBAR BASHA 40/M 554170D IWMI YES STK - - - + 
ARUMUGAM 44/M 554238D IW+RV YES STK + +- - + 
GOVINDA SWAMY 35/M 554262D AWMI YES STK + + + - 
ZABUNNISHA 48/F 554336D IW+PW YES STK - + + - 
SEKAR 45/M 554393D IW+RV YES STK + + + - 
AREEL SELVI 58/F 554403D LWMI YES STK + + + + 
ARUMUGAM 60/M 554448D AWMI YES STK + + - + 
MURUGESAN 60/M 554504D IW+RV YES STK - + - - 
SANKAR 56/M 554581D AWMI YES STK + + - + 
JAYACHANDRAN 66/M 554573D IW+RV YES STK + - + + 
PERUMAL 60/M 076983D IW+PW YES STK - - + + 
UMA 58/F 559201D AWMI YES STK - + + - 
RATHNAMANDVI 70/M 559246D IW+RV YES STK - + - + 
NAMCHIVEYAM 43/M 559234D IW+RV YES STK - _ - - 
THANGA VELU 68/M 563616D AWMI YES STK - + - - 
ABU 75/M 562009D AWMI YES STK - - - + 
CHINNAPPAN 72/M 157833D RV+LW YES STK + + + - 
PICHANDI 53/M 563692D IW+RV+PW YES STK + + + - 
DAKSHNAMOORTHY 48/M 563987D AWMI YES STK + + + - 
RAJA MANI 60/M 563554D AWMI YES STK + + + - 
SADAGOPAN 65/M 449298D AWMI YES STK - + - + 
SAMUEL VICTOR 62/M 561175D AWMI YES STK - - + - 
SELVARAJ 60/M 567349D IW+PW+LW YES STK - - + - 
RAMANATHAN 62/M 566798D IW+PW+LW YES STK + - + - 
MANICKAM 69/M 567386D AWMI YES STK + - - - 
MALAY ACHAY 49/M 562048D IWMI YES STK - - + + 
GOUTHAM  38/M 568511D ASMI YES STK - - + - 
MD ALI 52/M 572028D AWMI YES STK - - - + 
GNANASWAMY 74/F 572072D IWMI YES STK + +- - - 
PRABHU 47/M 572012D AWMI YES STK + + + - 
SEKAR 44/M 572170D ASMI YES STK - + + - 
DESINGU 60/M 572155D AWMI YES STK + + + - 
PANEER SELVAM 50/M 563605D ASMI NO - + + + + 
PATTAMAL 70/F 563997D AWMI NO - + + - - 
GOPAL M 65/M 559226D AWMI YES TNK - + - - 
NOVEMBER 2009 
 
     
    
NAME A/S H.N MI LYSED AGENT DM HTN DYS SMK 
SEKAR 44/M 572170D ASMI YES STK - - + + 
DESINGLU 60/M 572155D AWMI YES STK - + + - 
SHEKH RAHMATH 56/M 574016D AWMI YES STK - + - + 
DAKSHINAMOORTHY 68/M 572391D IW+RV+PW YES STK - _ - - 
THIYAGAN 60/M 572437D AWMI YES STK - + - - 
MOORTHY 53/M 572464D IW+RV+PW YES STK - - - + 
SALEEM AHMAD 42/M 572465D AWMI YES STK + + + - 
KANNIAH NAIDU 46/M 572467D ASMI YES STK + + + - 
VASANTHAN 60/M 831592A IW+RV YES STK + + + - 
SRINIVASAN 50/M 577024D IW+RV YES STK + + + - 
SAMIULLAH 48/M 577039D AWMI YES STK - + - + 
ISAI AMUTHA 52/M 577864D AWMI YES STK - - + - 
RAMAMOORTHY 60/M 577958D IW+RV+PW YES STK - + - + 
ABDUL MAJEED 71/M 577131D IW+PW YES STK - _ - - 
SUNDERMOORTHY 56/M 004300D IW+RV+PW YES STK - + - - 
BABU 55/M 577154D IW=RV YES STK - - - + 
ABDUL KHADAR 64/M 577179D AWMI YES STK + + + - 
LAKSHMANAN 59/M 577200D ASMI YES STK + + + - 
SARAVANAN 39/M 580631D AWMI YES STK + + + - 
SHAMEEN 60/M 577369D AWMI YES STK + + + - 
RADHAKRISHNAN 55/M 577430D AWMI YES STK - + - + 
GOPAL 45/M 577438D AWMI YES STK - - + - 
DURAISWAMY 50/M 577459D IWMI YES STK - - + - 
REDDAPPA 36/M 584128D AWMI YES STK + - + - 
BALAKRISNAN 50/M 583007D AWMI YES STK + - - - 
LOGANATHAN 53/M 582064D IW+RV YES STK - - + + 
GOUTHAMAM 48/M 582097D ASMI YES STK - - + - 
JEEWAMMA 45/F 575215D IW+RV YES STK - - - - 
MANIVANAN 45/M 582095D AWMI YES STK + +- - + 
RANGANYOGI 66/F 582173D IW+RV YES STK + + + - 
GOVINDASWAMY 90/M 582324D IW+RV YES STK - + + - 
MAHABOOB BASHA 59/M 647177C AWMI YES STK + + + - 
ALPHONSAAUGUSTIN 56/F 585641D IW+RV+PW YES STK + + + + 
NATESAN 65/M 582461D AWMI YES STK + + - + 
ARUMUGAM 53/M 582554D AWMI YES STK - + - - 
MOLA 48/M 588079D AWMI YES STK + + - + 
SAMPATH 75/M 588089D AWMI YES STK + - + + 
AHMED BASHA 35/M 588148D IWMI YES STK - - + + 
MANI 60/M 490277A IWMI YES STK - + + - 
PARSURAMAM 40/M 588210D AWMI YES STK - + - + 
KUMAR 55/M 588256D AWMI YES STK - _ - - 
BABU 47/M 591020D IW+RV YES STK - + - - 
THANGAMANI 46/M 591053D IW+RV YES STK - - - + 
VIVANATHAN 62/M 591215D AWMI YES STK + + + - 
SUBRAMANI 70/M 591218D AWMI YES STK + + + - 
RANGASAMY 60/M 591269D AWMI YES STK + + + - 
PRABHAKARAN 52/M 591316D IW+RV YES STK + + + - 
ILAYARAJAN 34/M 591369D IW+PW YES STK - + - + 
MURUGAIAN 62/M 591378D AWMI YES STK - - + - 
PATTAMAL 70/F 563997D AWMI NO - - - + - 
VISHWANATHAN 40/M 572195D AWMI NO - + - + - 
THEVUNA 51/M 563797D AWMI NO - + - - - 
DHANPAL 55/M 578871D AW+RBBB NO - - - + + 
JEWEL SARKAN 35/M 579778D IWMI NO - - - + - 
RAMESH 45/M 582344D ASMI NO - - - - + 
YASODAMMAL 70/F 592744B AWMI NO - + +- - + 
ESAN 71/M 480428D AWMI NO - + + + - 
NARAYANASWAMY 45/M 850868C IWMI NO - - + + - 
PASHAYAMMAL 76/F 591700D AWMI NO - + + + - 
SUBRAMANI 50/M 597146D IW+CHB NO - + + + + 
KANNAYIRAM 58/M 572593D AWMI YES TNK + + - + 
SUNDER RAJAN 59/M 585806A AWMI YES TNK - + - - 
SELVAM 62/M 591074D AWMI YES TNK + + - + 
RAVI 43/M 591331D AWMI YES TNK + - + + 
DECEMBER 2009 
 
     
    
NAME A/S H.N MI LYSED AGENT DM HTN DYS SMK 
MURUGESAN 60/M 591430D IW+RV YES STK - + - + 
PERUMAL 55/M 591412D IW+RV YES STK - _ - - 
SAMPATH 49/M 591501D AWMI YES STK - + - - 
SAI 55/M 591543D IW+RV YES STK - - - + 
JEYA KUMARI 61/F 591698D IW+RV YES STK + + + - 
GOVINDASWAMY 46/M 424592D IW+PW+RV YES STK + + + - 
JEEVARATHNAM 50/M 597135D IWMI YES STK + + + - 
MOHAN 42/M 597736D AWMI YES STK + + + - 
SHANMUGAM 66/M 292934A IWMI YES STK - + - + 
SHANMUGARAJ 62/M 469344C IW+RV YES STK - - + - 
VASUDEVAN 38/M 597301D AWMI YES STK - + - + 
RADHAKRISHNAN 52/M 625608C IWMI YES STK - _ - - 
ANWARA BEGUM 48/F 561521D AWMI YES STK - + - - 
THAMBI DURAI 55/M 597371D IW+RV YES STK - - - + 
BOOPALAN 52/M 597381D IW+RV YES STK + + + - 
ABDUL KHUDUS 35/M 557184D IWMI YES STK + + + - 
PURUSOTHAMAM 60/M 597463D IW+PW+RV YES STK + + + - 
KANNIAN 65/M 469839D AWMI YES STK + + + - 
NATARAJAN 52/M 603036D AWMI YES STK - + - + 
NITYANANDAN 63/M 603082D AWMI YES STK - - + - 
NEETHU KUMARI 26/F 603228D AWMI YES STK - - + - 
KUMAR 38/M 603264D IW+RV YES STK + - + - 
VINON  BABY 30/M 603259D AWMI YES STK + - - - 
KANNIAN 63/M 603466D AWMI YES STK - - + + 
RATIQ KHAN 50/M 607544D IW+PW YES STK - - + - 
THAGAVEL 65/M 609266D RV+PW YES STK - - - + 
CHINNARAJI 62/M 608441D AWMI YES STK + +- - + 
SIVALINGAM 62/M 608492D ASMI YES STK + + + - 
KANNIAN 50/M 608541D AWMI YES STK - + + - 
THIRUNAVUTIARASAN 55/M 608552D IW+RV YES STK + + + - 
KANAGARAJ 49/M 608096D AWMI YES STK + + + + 
VENKATARAMNA 60/M 613101D AWMI YES STK + + - + 
SAMPATH 42/M 613108D ASMI YES STK - + - - 
RAJARATHNAM 50/M 597220D IW+PW NO - + + - + 
RAJENDRA 52/M 597307D IW+RV NO - + - + + 
SARASWATHIAMMA 61/F 079019D AWMI NO - - - + - 
POKUDIAMMAL 90/F 603120D AWMI NO - - + + - 
KRISNAN KUTTINAIR 87/M 603273D IWMI NO - - + - + 
GOPAL 85/M 400348D ASMI NO - - _ - - 
JAGADAMMAL 52/F 608213D AWMI NO - - + - - 
GANESAN 56/M 087475D ASMI NO - - - - + 
VAITHIYALINGAM 70/M 608305D ASMI NO - + + + - 
SIVAJI 54/M 608535D AWMI NO - + + + - 
BALAJI 42/M 608438D AWMI NO - + + + - 
RAJAUPPAN 72/M 608576D AWMI NO - + + + - 
KAMALA 60/F 608004D ASMI NO - - + - - 
RAMASHANADNA 78/M 613117D ASMI NO  - - + - 
RAVI KUMAR 55/M 591453D AWMI YES TNK - - + - 
KUMAR 55/M 588256D AWMI YES TNK + - + - 
MARGABANDHU 65/M 604915D AWMI YES TNK + - - - 
VAITHYA LINGAM 70/M 608305D AWMI YES TNK - - + + 
PANEER SELVAM 68/M 582221D IWMI YES TNK - - + - 
PTCA 2009          
JANUARY 
 
     
    
GIRIBABU 34/M 355127D AWMI  PTCA + + + - 
MEENAKSI 51/M 389300D AWMI  PTCA - + + - 
JAMES 72/M 445656B AWMI  PTCA + + + - 
VARUTHAN 70/M 400045D IWMI  PTCA + + + + 
FEBRUARY  
 
     
    
DAMODARAN 55/M 410004D AWMI  PTCA - - + - 
RAJSEKARAN 47/M 410073D AWMI  PTCA + + - + 
RAMACHANDRAN 72/M 410137D IWMI  PTCA + - + + 
MANOKANAN 58/M 410799D AWMI  PTCA - - + + 
RAGAVAN 44/M 410170D AWMI  PTCA - + + - 
ARUMUGAM 63/M 412006D AWMI  PTCA - + - + 
VARADHAV 70/M 400045D IWMI  PTCA - _ - - 
THANGARAJ 28/M 400188D AWMI  PTCA - + - - 
SUGUMAR 42/M 400248D AWMI  PTCA - - - + 
SIMON 62/M 033789C IWMI  PTCA + + + - 
MARCH 
 
         
KANDASWAMY 49/M 417664D AWMI  PTCA + - - - 
SANKAR 28/M 417712D AWMI  PTCA + + + - 
SURYA KALA 48/F 378401D AWMI  PTCA - + - - 
MURUGESAN 60/M 419018D IWMI  PTCA - - + - 
BALAMMA 55/F 419068D AWMI  PTCA - + - - 
BHARATHI 60/F 422132D AWMI  PTCA - _ - - 
AMALAN JEYASEELAN 49/M 243885C AWMI  PTCA - + - - 
NARASIMHULU 62/M 422176D AWMI  PTCA - - - + 
GANANA SEKARAN 56/M 423819D AWMI  PTCA + + + - 
RADHARUKMANI 50/F 429107D AWMI  PTCA + + + - 
RAJAGOPAL 52/M 429250D AWMI  PTCA + + + - 
SREEVAMALA 65/M 429216D IWMI  PTCA + + + - 
APRIL 
 
         
GANESAN 57/M 436117D AWMI  PTCA - - + - 
MANOHARAN 66/M 436133D IWMI  PTCA - - + - 
THIRVANGADAM 87/M 447104D AWMI  PTCA + - + - 
BALUK PANDIT 47/M 446405D AWMI  PTCA + - - - 
MAY 
 
         
ANBARASU 50/M 709270B AWMI  PTCA - - + - 
KALAI ARASON 46/M 787110B AWMI  PTCA - - - + 
RAMA KUMAR 67/M 457127D IWMI  PTCA + +- - + 
KUMAR 53/M 457241D IWMI  PTCA + + + - 
JEBA KUMAR 59/M 740421A IWMI  PTCA - + + - 
JUNE 
 
         
MANIRATHINAM 52/M 469756D AWMI  PTCA + + + + 
ILLAYA RAJA 25/M 476717D AWMI  PTCA + + - + 
VITTOBA 58/M 480231D IWMI  PTCA - + - - 
MURUGESAN 51/M 484051D AWMI  PTCA + + - + 
JULY 
 
         
SOURIYAN HASRIS 58/M 490272D IWMI  PTCA - - + + 
SOUREY 53/M 403744D IWMI  PTCA - + + - 
KUMARAN 50/M 496339D IWMI  PTCA - + - + 
JACOB PREMANAND 47/M 493525D AWMI  PTCA - _ - - 
GOBEL ANDREWS 47/M 501436D AWMI  PTCA - + - - 
ESWARI 78/M 225555D AWMI  PTCA - - - + 
BALAKATACHALAM 60/M 457047D IWMI  PTCA + + + - 
AUGUST 
 
         
JUBIN 46/M 518110D IWMI  PTCA + + + - 
SRINIVASAN 26/M 518137D AWMI  PTCA + + + - 
WILLIGRAM 52/M 525488D AWMI  PTCA - + - + 
NIR MOHAMMAD 69/M 344116B AWMI  PTCA - - + - 
SEPTEMBER 
 
         
DHANPAL 57/M 959559A AWMI  PTCA + - + - 
UDHAYA SURAYAN 40/M 535451D AWMI  PTCA + - - - 
OCTOBER 
 
         
DELVANNI 60/F 554107D IWMI  PTCA - - + - 
SIVADAS 53/M 628714C IWMI  PTCA - - - + 
NAGARAJ 74/M 563503D AWMI  PTCA + +- - + 
RAJAREDDY 74/M 567363D IWMI  PTCA + + + - 
LALITHAMAL 66/F 567700D AWMI  PTCA - + + - 
SIMSON ADVENT 66/M 470043D IWMI  PTCA + + + - 
NOVEMBER 
 
         
KALIL A 50/M 578261D AWMI  PTCA + + - + 
CHANDRASEKAR 56/M 582194D AWMI  PTCA - + - - 
DECEMER 
 
         
CHANDRASEKAR 57/M 594299D IWMI  PTCA + - + + 
MARGABANDU 82/M 604915D AWMI  PTCA - - + + 
           
January 2010 
 
 
 
NAME A/S H.N MI LYSED AGENT DM HTN DYS SMK 
SENTHAMURI 48/M 110960D AWMI YES STK - _ - - 
AMEENBASHA 40/M 911046C IWMI YES STK - + - - 
ANTHONY 48/M 613175D AWMI YES STK - - - + 
SWAMINATHAN 47/M 220251D AWMI YES STK + + + - 
DURAI 48/M 613245D IWMI YES STK + + + - 
MANI 60/M 613263D AWMI YES STK + + + - 
GOVINDAN 49/M 611816D IW+PW YES STK + + + - 
MOHAN 45/M 613396D AWMI YES STK - + - + 
SRINIVASAN 36/M 614050D AWMI YES STK - - + - 
RAVENDRA 54/M 748410C IW+RV YES STK - + - + 
RAJA 47/M 449389B AWMI YES STK - _ - - 
VENKATESAN 43/M 613465D AWMI YES  STK - + - - 
PREMA 65/M 495449B AWMI NO STK - - - + 
VANAJA 32/F 616197D AWMI YES STK + + + - 
SAROJA 63/F 269661A AWMI YES STK + + + - 
PARAMASIVAM 67/M 075027C AWMI YES STK + + + - 
VEDANAYAGAM 57/M 616135D IW+PW YES TNK + + + - 
KUMARESAN 52/M 616111D IW+RV YES STK - + - + 
MOHAN 61/M 616228D AWMI YES STK - - + - 
SELVA ARASU 42/M 757536A AWMI YES STK - - + - 
KANNAIYSN 60/M 615789D IW+RV YES TNK + - + - 
DHANAMMA 64/F 870303 AWMI NO - + - - - 
SANKER 55/M 618100D AWMI YES STK - - + + 
NATARAJAN 57/M 023854D IW+RV YES STK - - + - 
JAYPAL 60/M 616322D AWMI YES STK - - - + 
ANNAMALEI 65/M 616346D LWMI YES STK + +- - + 
ANUMUGAM 57/M 616377D IW+RV YES STK + + + - 
VISHNU 65/M 426323B AWMI NO - - + + - 
BHAKIA RAJ 33/M 616370D AWMI Yes STK + + + - 
SAROJA 60/F 269661A AWMI NO - + + + - 
VIJAYA 60/F 566423D AWMI YES STK + + - - 
SARAVANAN 44/M 620067D IW+RV YES STK - + - - 
KASTHURI 50/F 620079D IW+RV YES STK + + - - 
MUTHIYALAL 52/M 620105D IW+RV YES STK + - + + 
JANIMMA 50/F 620170D IW+RV YES STK - - + + 
KANNAN 60/M 620309D IW+RV YES STK - + + - 
KASINATHANAN 60/M 429307B AWMI NO - - + - + 
KANTA 36/F 620325D AWMI YES STK - _ - - 
SANDHU 57/M 620324D AWMI YES STK - + - - 
ABDUL  61/M 621365D AWMI YES STK - - - + 
MADANGOPAL 64/M 620379D AWMI YES STK + + + - 
SAIDAR 40/M 505401D IW+RV YES STK + + + - 
ANUMUGAM 62/M 620451D AWMI NO - + + + - 
MAHALINGAM 48/M 620457D IW+RV YES STK + + + - 
RATHINAM 64/M 620459D IW+RV YES STK - + - + 
TAMILSELVAM 27/M 620472D IW+RV YES STK - - + - 
KANTHA 36/F 620325D AWMI YES STK - - + - 
DASARATHAN 51/M 893981C IW+RV YES STK + - + - 
VOMEATESAN 42/M 620503D AWMI YES STK + - - - 
VENKATESAN 52M 918665A AWMI YES STK - - + + 
ABDUL 57/M 523861D IW+RV YES STK - - + - 
ANNAMALAI 56/M 117119B AWMI YES STK - - - + 
PERUMAL 39/F 625120D AWMI YES STK + +- - - 
SHANKER 41/M 625151D AWMI YES STK + + + - 
KRISHNAN 80/M 625156D AWMI YES STK - + + - 
UDAYA 34/M 625179D IWMI YES TNK + + + - 
SUBRAMANI 64/M 625160D AWMI NO - + + + + 
BANUMATHI 52/F 625190D AWMI YES STK - + - + 
GANAPATHY 42/M 625196D IW+RV YES STK - _ - - 
MANOKANAN 50/M 625248D AWMI YES STK - + - - 
KASTHURI 64/F 626719D AWMI YES STK - - - - 
HASSAN 58/M 626599D AWMI NO - + + + - 
BABISMMAL 52/F 627836D IW+RV YES STK + + + - 
RAMALINGAM 65/M 628303D AWMI YES STK + + + - 
SHANMUGAM 46/M 625293D AWMI YES STK + + + - 
RAMACHANDRAN 66/M 613259D AW+LW NO  - + - + 
RAJAMANICKAM 47/M 449389B AWMI YES STK - - + - 
SETAMMAL 66/F 616065D IW+RV YES STK - - + - 
WILSON 68/M 870303B IW+PW YES STK + - + - 
PALANI 54/M 616207D IW+RV YES STK + - - - 
SWAMINATHAN 46/M 220251D AWMI YES STK - - + + 
SELVA ARAJAN 42/M 757536D AWMI YES STK - - + - 
ANNAMALAI 68/M 616346D LWMI YES STK - - - + 
SHANKAR 55/M 618100D AWMI YES STK + +- - + 
MOHAN 43/M 613396D AWMI YES STK + + + - 
February 2010 
 
     
    
Gunasundaran 79/M 625463D AWMI YES STK + + + - 
Meenakshi 61/F 034772C AWMI YES STK + + + - 
Kothandamal 55/M 625337D AWMI YES STK + + - + 
Shankar 31/M 025594D IW+RV YES STK - + - - 
Kalyansundaram 48/M 630055D AWMI YES STK + + - + 
Sakunthalamma 75/F 630064D AWMI NO - + - + - 
Venkateshwar 36/M 630160D AWMI YES STK - - + + 
Venkatedri eddy 51/M 630176D IW+RV YES STK - + + - 
Nithyanandan 53/M 630260D AWMI YES STK - + - + 
Delhibabu 62/M 634068D AWMI YES STK - _ - - 
Srinivaan 56/M 630425D AWMI YES STK - + - - 
Maniuel 68/M 630450D AWMI YES STK - - - + 
Subramanium 75/M 630440D AWMI YES STK + + + - 
Bhavani B 57/F 630462D AWMI NO - + + + - 
Arvind Pandey 55/M 538727C AWMI YES STK + + + - 
Yuvaraj 45/M 625211D AWMI YES STK + + + - 
Rajaram 38/M 634402D AWMI NO - - + - + 
Dasnagir 42/M 630499D AWMI YES STK - - + - 
Narasimhr eddy 84/M 638107D AWMI NO - - - + - 
Gopal 70/M 638125D AWMI YES STK + - + - 
Balarman 64/M 638731D AWMI YES TNK + - - - 
Sekar 49/M 638185D IWMI YES STK - - + + 
Banumathy 50/F 625190D AWMI NO - - - + - 
Chandrasekar 29/M 638391D IW+RV YES STK - - - + 
Govindarajan 59/M 639618D AWMI NO - + +- - + 
Sundarmoorthy 49/M 637685D IW+PW YES STK + + + - 
Sundarmoorthy 55/M 282666C IWMI YES STK - + + - 
Raja 47/M 638254D AWMI YES STK + + + - 
Rangemmal 60/M 638266D AWMI YES STK + + + + 
Prabhakaran 45/M 638423D AWMI YES STK + + - + 
Logaligam 64/M 638471D AWMI YES STK - + - - 
Shanmugam 76/M 638479D AWMI YES STK + + - + 
Samad bebi 65/F 641092D LWMI YES STK + - + - 
Rajammal 85/F 638496D IWM YES STK - - + + 
Vanathiyan 53/M 638530D IW+RV YES STK - + + - 
Mehrunisha 60/F 638536D IW+RV YES STK - + - + 
Kangaraj 47/M 644146D IW+RV YES STK - _ - - 
Madan Mohan 58/M 642684D IW+RV YES STK - + - - 
Kannamal 55/F 644157D IW+RV YES STK - - - - 
Murgesan 47/M 644154D AWMI YES STK + + + - 
Jagathambal 80/F 960186C IWMI YES STK + + + - 
Vairavan 68/M 127322D IWM NO - + + + - 
Runsathanam 59/M 644215D AWMI YES STK + + + - 
Ponnuswami 51/M 644218D IWMI YES STK - + - + 
Indirani 70/F 645193D IW+RV YES STK - _ - - 
Narayanan 62/M 644224D AWMI YES STK - + - - 
Abduka Suban 40/M 645865D AWMI NO - - - - + 
Anand 70/M 644230D AWMI YES STK + + + - 
Murugan 50/M 644271D IWMI YES STK + + + - 
Rathinammal 58/F 644355D IW+RV YES STK + + + - 
Kasinathan 52/M 795701A IW+RV YES STK + + + - 
LOGANATHAN 52/M 630264D IW+LW YES STK - + - + 
BHAVANI 54/M 630462D AWMI NO  - - + - 
LAKSHMI 52/M 634460D IWMI YES URO - - + - 
RANGAMMAL 60/F 638266D AWMI YES STK + - + - 
PERUMAL 85/M 638476D AWMI YES STK + - - - 
SAMAD BEVI 65/F 641092D IW+RV YES STK - - + + 
RADHAKRISHNAN 51/M 638531D IW+RV YES STK - - + - 
MALLICK BASHA 65/M 638509D IWMI YES STK - - - + 
SHANKAR KUMAR 60/M 640475D AWMI YES STK + +- - + 
MARANDICPEN 56/M 644353D AWMI TES TNK + + + - 
March 2010 
 
         
NAME A/S HN MI LYSED AGENT DM HTN Dys Smo 
Munawar  38/M 644395D IW+RV YES STK - + - + 
Siva Reddy 32/M 648014D AWMI YES STK - _ - - 
Viayagam 75/M 400268D AWMI YES STK - + - - 
Govindan 49/M 648018D AWMI YES STK - - - + 
Ambikaammal 75/F 648167D AWMI YES STK + + + - 
Boopalan 59/M 648174D AWMI NO - + + + - 
Annamalai 80/M 649330D AWMI NO - + + + - 
Panchvarnam 70/F 868590C AWMI YES STK + + + - 
Manoharan 35/M 648271D AWMI YES STK - + - + 
Krishen 53/M 648305D IW+RV YES STK - - + - 
Thirumal Raj 65/M 648329D IWMI NO - - - + - 
Vinayagram 75/M 406268D AWMI NO - + - + - 
Vilvijayan 52/M 131922D AWMI YES STK + - - - 
Murali 47/M 648362D IW+RV YES STK - - + + 
Lalitha 57/F 648368D IW+RV YES STK - - + - 
Tharammal 59/F 648380D IW+RV YES STK - - - - 
Neelakandan 58/M 651305D IW+RV YES STK + +- - + 
Gopal 65/M 651348D AWMI YES STK + + + - 
Dhanpal 59/M 650966D AWMI YES STK - + + - 
Hasintaj 51/F 651921D AWMI NO - + + + - 
Jayalaksmi 52/F 652301D IW+RV YES STK + + + - 
Elumalai 34/M 653506D AWMI YES STK + + - + 
Velu 36/M 678968D LWMI YES STK - + - - 
Kannamal 70/F 658143D LWMI YES STK + + - - 
Sumit Kumar 55/M 650115D AWMI YES STK + - + + 
Govindaraj 68/M 658204D AWMI YES STK - - + + 
Arumugam 68/M 890264A AWMI NO - - + + - 
Vinayagam 68/M 658275D IW+RV YES STK - + - + 
Santakumari 62/F 659234D IWMI YES STK - _ - - 
Rajammal 79/F 660014D AWMI NO - - + - - 
Kumaravel 39/M 660345D IWMI NO - - - - + 
Subramani 58/M 660912D AWMI YES STK + + + - 
Arvindasen 60/M 658345D IW+RV YES STK + + + - 
Devarajulu 58/M 658373D AWMI YES STK + + + - 
Prabhakaran 28/M 658377D IWMI NO - + + + - 
Sumathi 57/F 897813B AWMI NO - - + - - 
Narsimhan 70/M 661089D IW+RV YES STK - - + - 
Parvathi 70/F 661099D AWMI YES STK - - + - 
Manoharan 46/M 661170D AWMI YES STK + - + - 
Thangavelu 70/M 664337D IW+RV YES STK + - - - 
Karunakaran 55/M 664335D AWMI YES STK - - + + 
Radhakrishanan 65/M 661232D IW+RV YES TNK - - + - 
Shanmugam 71/M 661236D AWMI YES STK - - - + 
Leslee 58/M 210971D IW+LW YES STK + +- - + 
Sivanandhan 22/M 700914B IWMI YES STK + + + - 
Mahendran 51/M 661267D AWMI YES STK - + + - 
Nithyanandan 72/M 616442D IW+RV YES STK + + + - 
Naglingam 59/M 661428D IWMI YES STK + + + + 
Abdul Ali 65/M 661458D IW+PW YES STK + + - + 
Subramani 65/M 667858D IW+PW YES STK - + - - 
Bathula Bee 65/F 661595D AWMI YES STK + + - - 
Sukumar 32/M 661598D AWMI YES STK + - + + 
RATHINAMMAL 58/F 644355D IW+RV YES STK - - + + 
MUNAWAR AHMED 38/M 644397D IW+RV YES STK - + + - 
JAYALAKSHMI 52/F 652301D AWMI YES STK - + - + 
GOPAL 65/M 651348D IWMI YES STK - _ - - 
DHANPAL 59/M 650966D AWMI YES STK - + - - 
PARWATHY 70/F 661099D AWMI YES STK - - - - 
KARUNAKARAN 64/M 661276D AWMI YES STK + + + - 
SHANMUGAM 71/M 661236D AWMI YES STK + + + - 
RANGASWAMY 48/M 669404D AWMI YES TNK + + + - 
MURALIDHARAN 36/M 648399D IW+RV YES TNK + + + - 
APRIL 2010 
 
     
    
NAME A/S H.N MI LYSED AGENT DM HTN DYS SMK 
Murugesan 40/M 669473d IW+RV NO - - - + - 
Chinnathampi 65/M 669506d AWMI Yes STK - + - + 
Subramani 40/M 669657d AWMI Yes STK - _ - - 
Sarvanan 37/M 000253d IWMI Yes STK - + - - 
AnwarBasha 60/M 669671d AWMI NO - - - - + 
Yesudas 59/M 669747d AWMI Yes STK + + + - 
Kelliamba 80/F 037916d IW+RV Yes STK + + + - 
Babu 45/M 669794d IW+RV NO - + + + - 
Rajammal 80/F 660014d AWMI Yes  STK + + + - 
Muthuswami 70/M 663686d AWMI Yes STK - + - + 
Aramugam 68/M 669850d IW+RV Yes STK - - + - 
Mohd Karim 70/M 669932d AWMI Yes STK - - + - 
Ramu 45/M 669960d IWMI Yes STK + - + - 
Kannadesam 57/M 164736d AWMI Yes STK + - - - 
Damodaran 62/M 670000d AWMI Yes STK - - + + 
Gunasundari 68/M 670023d IW+PW NO - - - + - 
Sohramani 60/M 667858d IW+RV Yes STK - - - + 
Naarajan 75/M 674099d IW+RV Yes STK + +- - + 
Jayantikumari 57/M 157963c AWMI Yes STK + + + - 
Kishan 63/M 674140d IW+RV Yes STK - + + - 
Rajesh Kumar 28/M 674216d IW+RV Yes STK + + + - 
Vekata ratha 59/M 674219d IW+RV Yes STK + + + + 
Seshachalan 63/M 345436c IW+RV Yes STK + + - + 
Mohanan 59/M 893280c IWMI NO - - + - - 
Sarvanan 28/M 674274d AWMI Yes STK + + - + 
Vijay kumar 36/M 674288d AWMI Yes STK + - + + 
Shantha kumar 50/F 674281d IW+RV Yes STK - - + - 
Ganeshan 41/M 674282d AWMI Yes STK - + + - 
Chinnathambi 75/M 674303d IWMI NO - - + - + 
Shahai joseph 48/M 601302d AWMI Yes STK - _ - - 
Murgesh 41/M 676818d AWMI Yes STK - + - - 
Ibrahim  44/M 559287d AWMI NO - - - - + 
Dharani  53/F 677966d AWMI Yes STK + + + - 
Govaidasami 50/M 400636c AWMI Yes STK + + + - 
Subramani 55/M 674510d IW+RV Yes STK + + + - 
Salauddin 65/M 675776d AWMI Yes STK + + + - 
Elumalai 33/M 674521d AWMI Yes STK - + - + 
Mahadevan 52/M 674556d AWMI NO - - - + - 
Sampathraj 57/M 478548d IW+PW NO - - - + - 
Knnairam 64/M 680030d IW+RV Yes STK + - + - 
Innayathullah 56/M 680035d AWMI Yes STK + - - - 
Mohd Basha 52/M 680039d AWMI Yes STK - - + + 
Munniah 51/M 512596c AWM I Yes TNK - - + - 
Budamalai 53/M 387697d AWMI Yes STK - - - + 
Mutthu 57/M 680199d AWMI Yes STK - + - + 
Venkatesh 45/M 680206d AWMI Yes STK - _ - - 
Faiz Ahmed 37/F 893192c AWMI Yes STK - + - - 
Chan Begum 73/F 242507c AW MI Yes STK - - - - 
Rajareddy 37/M 680241d AWMI Yes STK + + + - 
Jothiranjan 48/M 680884d AWMI Yes STK + + + - 
Gangadharan 84/M 999274c IW+LW Yes STK + + + - 
Selvaraj 66/M 681889d AWMI YES STK + + + - 
Murgesan 54/M 680353d AWMI YES STK - + - + 
Janagiraman 70/F 680898d IW+RV YES STK - - + - 
Selvaraj 45/M 686062d AWMI YES STK - - + - 
Mohd Allah 60/M 686088d AWMI YES STK + - + - 
Kaderbasha 55/M 686115d AWMI YES STK + - - - 
Sabun  52/M 686162d AWMI NO - - - + + 
Durai 44/M 686164d AWMI YES STK - - + - 
Narasimah 75/M 687724d IW+RV YES STK - - - + 
Udaisankar 78/M 687580d IW+RV YES STK + +- - + 
Samuel 60M 686229d AWMI YES STK + + + - 
Paneerselvum 50/M 102959c IW+RV YES STK - + + - 
Kumar 40/M 669676d AWMI YES STK + + + - 
SARVANAN 28/M 674274D ASMI YES STK + + + + 
GANGADHARN 53/M 674316D AWMI YES STK + + - + 
NISAHAYA JOSEPH 48/M 601302C ASMI YES STK - + - - 
DURAI 60/M 682042D IWMI NO  + + - + 
KARUNAKARAN 56/M 511753D AWMI YES STK + - + + 
CHANDRAN 53/M 682987D IW+RV YES STK - - + + 
PALANI 49/M 069278B IW+PW+LW NO  - + + - 
SELVARAJ 66/M 681889D AWMI YES STK - + - + 
MAY 2010 
 
     
    
Name A/S H.No MI LYESD Agent DM HTN DYS SMK- 
Mohanavelu                   60/M 688877D AWMI Yes STK - - - + 
Ramanan 45/M 686269D IW+RV Yes STK + + + - 
Janakiraman 62/M 686270C AWMI No - + + + - 
Ananolan 60/M 686421D AWMI Yes STK + + + - 
Vijayakumar 50/M 686451D AWMI Yes STK + + + - 
Ramachandran 34/M 686516D AWMI Yes STK - + - + 
Sivaprakasan 50/M 686532D IW+RV Yes STK - - + - 
Chanbasha 48/M 686583D AWMI Yes STK - - + - 
Ramachandran 58/M 686516D AWMI No   - + - + - 
Dhanpal 59/M 650966D AWMI No  - + - - - 
Vairavan 66/M 692215D IW+RV Yes STK - - + + 
Thyagrajan 53/M 692339D AWMI Yes STK - - + - 
Babu 49/M 692758d IWMI Yes STK - - - + 
Manikandan 70/M 693094d AWMI Yes STK + +- - + 
Elumalai 35/M 693208d IW+RV Yes STK + + + - 
Balaram 58/M 693213d IW+RV Yes STK - + + - 
Samiappan 70/M 693241d IW+RV No - + + + - 
Gajendran 60/M 693248d IW+RV  Yes STK + + + + 
Rafeeq 65/M 693319d AWMI Yes STK + + - + 
Kumar 55/M 693305d IW+RV Yes STK - + - - 
Ravindran 48/M 695372d AWMI Yes STK + + - + 
Munniswamy 62/M 697034d AWMI Yes STK + - + + 
Mohanvelu 59/M 693381d AWMI Yes STK - - + + 
Peterarunugam 62/M 693394d IW+RV Yes STK - + + - 
Nesmani 62/F 693397d IW+RV Yes STK - + - - 
Ramachandran 70/M 693399d AWMI No - - _ - - 
Dayalan 60/M 693473d AWMI Yes STK - + - - 
Susanna 62/M 693495d AWMI Yes STK - - - + 
Sekharpaul 52/M 690057d IW+RV Yes STK + + + - 
Ekambaran 60/M 693532d AWMI Yes STK + + + - 
Alliabee 65/F 693541d AWMI Yes STK + + + - 
Changamnaidu 70/M 693590d IW+RV Yes STK + + + - 
Amaravati 65/F 701310D AWMI Yes  STK - + - - 
Jyachandran 23/M 697852D AWMI Yes STK - - + - 
Saffiruddin 60/M 701133D AW MI Yes STK - + - + 
Anand sekar 53/M 698312D AWMI No - - _ - - 
Sundaram 52/M 698822D AWMI Yes STK - + - - 
Munniyappan 60/M 699685D AWMI No - - - - + 
Udaivelu 69/M 591322B IWMI No - + + + - 
Velu 55/M 702448D AWMI Yes STK + + + - 
Venkatesan 35/M 701501D AWMI Yes STK + + + - 
Selvaraj 66/M 701502D IW+RV Yes STK + + + - 
Deviki 60/F 649808B IWMI Yes STK - + - - 
Periyaswami 75/M 965795B AWMI Yes STK - - + - 
Tamilselvi 40/F 867861B AWMI Yes STK - - + - 
Dayalan 58/M 229457C AWMI Yes STK + - + - 
Sugana 70/F 701417D AWMI Yes TNK + - - - 
Shansheery 68/M 704518D AWMI Yes STK - - + + 
Thirupuram 60/F 264216D AWMI Yes STK - - + - 
Arumugam 50/M 701476D AWMI Yes STK - - - + 
Durairaj 53/M 708059D IW+RV Yes STK + +- - + 
Raju 56/M 704149D AWMI Yes STK + + + - 
Geetha 45/F 708064D AWMI Yes STK - + + - 
Thirumalai 69/M 705494D AWMI Yes STK + + + - 
Arumugam 58/M 582554D IW+MI Yes URO + + + + 
Koteswari 74/F 708183D AWMI Yes STK + + - - 
Shanmugam 45/M 708236D IW+RV Yes STK - + - - 
Umarani 52/F 708262D IWMI Yes STK + + - - 
Rahgu 55/M 704149D AWMI Yes STK + - + + 
Ranjan 39/M 708287D AWMI Yes STK - - + + 
CHANBASHA 55/M 686583D AWMI YES STK - + + - 
RAVINDRAN 41/M 695372D AWMI YES STK - + - + 
MEENAKSHI 47/F 693051D AWMI YES STK - _ - - 
SOURIYAPPAN 71/M 693241D IW+PW+RV NO  - + - - 
PONNUSWAMY 62/M 697034D AWMI YES STK - - - + 
PARANTHAMAN 60/M 693534D IWMI YES STK + + + - 
SUSANA 66/M 693495D ASMI YES STK + + + - 
SAMPATH 62/M 701332D IW+LW YES STK + + + - 
RAJKUMAR 56/M 701391D IW+RV YES STK + + + - 
SUNDARAM 56/M 698822D AWMI YES STK - + - + 
MOHANVELLU 57/M 643381D AWMI YES STK - - + - 
SELVARAJ 60/M 701520D IW+RV YES STK - - + - 
MOHAN NAIDU 59/M 905048A AWMI YES STK + - + - 
JAYARAMAN 55/M 689326D AWMI YES STK + - - - 
JAYASEELAM 55/M 397506C AWMI YES STK - - + + 
DAYALAN 52/M 229457C AWMI YES STK - - + - 
RAVINDRAN 42/M 695372D AWMI YES STK - - - + 
KRISHANAN 69/M 157364C IW+PW YES TNK + +- - + 
KOTTESWARIAMMAL 75/M 708183D IW+RV YES STK + + + - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
JUNE 2010 
 
NAME 
A/S HN MI Lysed Agent DM HT Dys Smo 
Anantpadmanabhan 45/M 708334d AWMI yes STK + + - + 
Siva 38/M 707389d AWMI yes STK - + - - 
Pradhalan 52/M 709131D AWMI No - + + - + 
Vijay 23/M 682383D AWMI No - + - + + 
Bothukesavan 58/M 711010D AWMI Yes STK - - + + 
Babu 62/M 703508D IW+RV Yes STK - + + - 
Krishnamoorthy 69/M 708526D AWMI Yes TNK - + - + 
Kalyani 45/M 1699489C AWMI Yes STK - _ - - 
Sekar 49/M 457330C IW+RV Yes TNK - + - - 
Venkatesan 49/M 712144D AWMI Yes STK - - - + 
ThirumalaiNaidu 69/M 712138D AWMI Yes STK + + + - 
Ahmed Basha 52/M 712178D IW+RV Yes TNK + + + - 
Samson 39/M 711097D IW+RV Yes STK + + + - 
Natarajan 57/M 712228D AWMI Yes STK + + + - 
Sakthivel 50/M 714819D AWMI Yes STK - + - + 
Jambulingam 68/M 713363D AWMI Yes STK - - + - 
Chandrasekhar 56/M 713150D AWMI Yes STK - - + - 
Subramani 74/M 712260D AWMI Yes STK + - + - 
Kumarvel 39/M 712305D AWMI Yes STK + - - - 
Sagunthala 68/F 712354D AWMI Yes STK - - + - 
Aruldas 36/M 712352D AWMI Yes STK - - + - 
Gandhi 65/M 712400D AWMI Yes STK - - - + 
Narayanan 78/M 758755D AWMI Yes STK + +- - + 
Govindaraj 70/M 712468D IW+RV Yes STK + + + - 
Lakhsiammal 75/F 712510D AWMI Yes TNK - + + - 
Ramesh Babu 44/M 716351D AWMI Yes STK + + + - 
Boopethi 45/M 716442D AWMI Yes STK + + + + 
Rajendran 56/F 716372D AWMI Yes STK + + - - 
Nagarajan 68/M 606139D AWMI Yes TNK - + - - 
Salim  Basha 51/M 71222D AWMI Yes STK + + - + 
Syed Mustafa 52/M 720470D IW+RV Yes STK + - + + 
Hasmuthullah 55/M 719009D AWMI No - - - + + 
Bhanuprasad Das 64/M 712598D IW+RV Yes STK - + + - 
Gopal 65/M 719008D IW+RV Yes STK - + - + 
Manglalakhsmi 66/F 141456D AWMI Yes STK - _ - - 
Nagappan 39/M 719055D AWMI Yes TNK - + - - 
Mahalingam 56/M 719056D AWMI No STK - - - + 
Vijayan 54/M 719106D AWMI Yes STK + + + - 
Kastoori 45/F 719136D AWMI Yes STK + + + - 
Kuppu 60/M 719280D IW+RV No - + + + - 
Gnanalekha 31/M 488533D IW+RV No - + + + - 
Punniah 55/M 719474D IW+RV Yes STK - + - + 
Gopal 60/M 719485D AWMI Yes STK - - + - 
Sundarmoorthy 62/M 111186D AWMI No - - - + - 
Teekaram 40/M 722623D AWMI Yes STK + - + - 
Yuvaraj 27/M 723087D IW+RV Yes STK + - - - 
Shankar 55/M 723503D AWMI Yes STK - - + + 
Senthilvelan 47/M 723659D AWMI Yes STK - - + - 
Muniswamy 70/M 725280D IW+RV Yes STK - - - + 
Malliga 73/F 719555D AWMI Yes TNK + +- - - 
Sundarammal 78/F 726181D IWMI Yes STK + + + - 
SathishBabu 39/M 693353D AWMI Yes STK - + + - 
Nazeer 65/M 719598D AWMI Yes STK + + + - 
Anbalangam 45/M 724011D AWMI No STK + + + + 
Preethi 55/F 724024D AWMI No STK + + - - 
Selvum 34/M 122487D AWMI Yes STK - + - - 
Anthony 70/M 461397 IW+RV Yes STK + + - + 
Govindaswami 50/M 724113D AWMI Yes TNK + - + + 
Saraswati 55/F 288347D AWMI Yes STK - - + - 
Duraiswamy 75/M 724178D AWMI Yes STK - + + - 
Rangasami 62/M 724176D AWMI Yes STK - + - + 
Vijayan 45/M 724183D AWMI Yes STK - _ - - 
Sigamani 55/M 719417D IW+RV Yes STK - + - - 
Banu 45/M 724213D IW+RV Yes STK - - - + 
Malarkodi 52/F 724227D IWMI No - + + + - 
NATARAJAN 66/M 711027D ASMI YES STK + + + - 
KUPPAN 52/M 712367D IW+RV YES STK + + + - 
SUNDARAMMA 72/M 726181D IW+PW+RV YES STK + + + - 
TEEKARAM 40/M 722623D AWMI YES STK - + - + 
JAYAVELU 63/M 939010C AWMI YES TNK - - + - 
 
JULY 2010 
         
Nandasekar Reddy 55/M 724342D AWMI Yes STK - - + - 
Krappagan 59/M 724316D AWMI Yes STK + - + - 
Kulsar 31/M 724366D AWMI Yes STK + - - - 
Krishnamoorthy 66/M 724387D AWMI Yes TNK - - + + 
Govindasami 61/M 724383D IW+RV Yes STK - - + - 
Sundermmal 58/M 724405D IW+RV Yes TNK - - - + 
Venketesan 70/M 728334D AWMI Yes TNK + +- - + 
Ramathilagan 85/M 724441D IW+RV Yes STK + + + - 
Mani 63/M 724442D IW+RV Yes TNK - + + - 
Appudurai 54/M 945904c AWMI Yes STK + + + - 
Jayakumar 50/M 730057d AWMI Yes STK + + + + 
Ramamoorthy 42/M 730078d AWMI Yes STK + + - + 
Valliammal 70/F 729989d IW+RV Yes STK - + - - 
Shanthivel 40/M 731143d AWMI Yes STK + + - + 
Dhansekaran 51/M 730251d AWMI Yes TNK + - + + 
Manohar 43/M 184524d AWMI Yes STK - - + + 
Vendan 44/M 730275d AWMI No - - + + - 
Gunalan 58/M 733964d AWMI No - - + - + 
Arjunan 62/M 730350d IW+RV Yes STK - _ - - 
Narayansami 66/M 730348d AWMI No - - + - - 
Pappuammal 70/F 724540D IW+RV Yes STK - - - - 
Bhaskaran 52/M 724581D IWMI Yes STK + + + - 
Munirathinam 55/M 724580D IW+RV Yes STK + + + - 
Subramani 60/M 724585D AWMI Yes STK + + + - 
Kumar 49/M 724595D AWMI No STK + + + - 
Yasodammal 60/F 724565D IW+RV Yes STK - + - - 
Sekar 45/M 735027D AWMI Yes STK - - + - 
Muniah 54/M 735048D IW+LW Yes TNK - - + - 
Manokaran 46/M 625248D AWMI Yes STK + - + - 
Thomas 61/M 735088D IW+RV Yes STK + - - - 
Kamaciammal 55/F 737719D AWMI Yes STK - - + - 
Abdul Mallick 52/M 735267D AWMI Yes STK - - + - 
Jagannathan 60/M 739120D AWMI Yes TNK - - - + 
Asmath Bee 60/F 083816C IW+RV Yes STK + +- - + 
Koteswari 60/F 739117D IW+RV Yes STK + + + - 
GANAPATHY 77/M 303379B IWMI NO  - + + - 
CHENGI CHINNA 73/M 735048D IW+LW YES TNK + + + - 
KEWLLACHAMMAL 55/M 737719D AWMI YES STK + + + + 
VARAMARY 60/F 242883C IWMI NO  + + - - 
VARAYAPPA 74/M 739313D IW+LW+PW YES TNK - + - - 
SONIPATH 45/M 742350D IW+LW+PW+R
V 
YES STK + + - + 
MUNNAR 56/M 902634C AWMI NO - + - + + 
ANNAMALAI 55/M 744160D AWMI NO - - - + + 
NASUMA 48/F 744397D AWMI YES STK - + + - 
Murgesan 4//M 739195D AWMI Yes STK - + - + 
Radhakrishnan 82/M 562735C AWMI No - - _ - - 
Devadoss 44/M 739336D AWMI Yes STK - + - - 
M.k Krishnan 59/M 643752D IWMI Yes STK - - - + 
Shaguntala 50/F 492175D AWMI Yes STK + + + - 
Raju 70/M 750116D IWMI No - + + + - 
Manuswami 50/ M 750145d AWMI Yes STK + + + - 
Sethuraja 58/M 445029d AWMI Yes STK + + + - 
Gopal 50/M 750156d AWMI Yes STK - + - + 
Amritha 40/F 742404D AWMI Yes STK - - + - 
Krishna 72/M 742576D IW+PW Yes STK - - + - 
Shanmugam 62/M 739350D IWMI No - + - + - 
Mohd Farooq 55/M 742429D AWMI No STK + - - - 
Krishnamoorthy 55/M 742393D AWMI No STK - - + + 
Ranganathan 62/M 735349D AWMI Yes STK - - + - 
Sikander 59/M 634162D AWMI Yes STK - - - + 
Satya 52/M 737329D AWMI Yes STK + +- - + 
Nagarithanam 56/F 999377C AWMI Yes STK + + + - 
Kadirvelu 50/M 727580C AWMI No - - + + - 
Ramamoorthy 64/M 744315D IW+RV Yes STK + + + - 
KatharBasha 40/M 709984C AWMI Yes STK + + + + 
Moorthy 51/M 747846D AWMI Yes STK + + - + 
Mani 55/M 744156D AWMI Yes STK - + - - 
Mohd Sarfaraz 60/M 744349D IW+RV Yes STK + + - + 
Elambaran 35/M 744351D AWMI No STK + - + + 
Srilatha 44/F 744371D AWMI Yes STK - - + - 
GANESH BABU 47/M 609280D IW+RV+PW - PTCA - + + - 
SWAMINATHAN 76/M 613178D AWMI - PTCA - + - + 
AMBARASAN 64/M 613473D AWMI - PTCA - _ - - 
GOPAL 67/M 613484D AWMI - PTCA - + - - 
MANI 67/M 616227D AWMI - PTCA - - - + 
KUMAR 48/M 616380D IW+RV - PTCA + + + - 
MITTALAL JAIN 58/M 616375D AWMI - PTCA + + + - 
MADHIYAZHAGAN 63/M 625580D AWMI - PTCA + + + - 
JAGANNATHAN RAO 52/M 634946D AWMI - PTCA + + + - 
GOVINDASWAMY 62/M 251169D IWMI - PTCA - + - + 
SUNDARESAN 54/M 638450D AWMI - PTCA - - + - 
ABDUL MALLICK 47/M 638499D IW+RV - PTCA - - + - 
SHUK SALEEM 40/M 648117D AWMI - PTCA + - + - 
PRABHAKAR 63/M 165122B AWMI - PTCA + - - - 
KANDASWAMY 81/M 648387D AWMI - PTCA - - + + 
VINAYAGAM 75/M 400268D AWMI - PTCA - - + - 
MURALI 46/M 648362D AWMI - PTCA - - - + 
KIRUV BAKARAN 54/M 932578A IW+LW - PTCA + +- - + 
SUNDARJI 56/M 658238D IW+PW+RV - PTCA + + + - 
DHANAMAL SURANA 60/M 426066C AWMI - PTCA - + + - 
SIVARAJ 51/M 658394D AWMI - PTCA + + + - 
 
